glyburide has been researched along with Diabetes Mellitus in 416 studies
Glyburide: An antidiabetic sulfonylurea derivative with actions like those of chlorpropamide
glyburide : An N-sulfonylurea that is acetohexamide in which the acetyl group is replaced by a 2-(5-chloro-2-methoxybenzamido)ethyl group.
Diabetes Mellitus: A heterogeneous group of disorders characterized by HYPERGLYCEMIA and GLUCOSE INTOLERANCE.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM)." | 9.12 | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| "The effect of glibenclamide and gliquidone on fasting blood glucose, 24-hour urinary glucose excretion, HbA1 concentrations and on the blood glucose and plasma insulin responses to an oral glucose load were investigated in 11 patients with non-insulin-dependent diabetes mellitus." | 9.05 | Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus. ( Groop, L; Nikkilä, K, 1982) |
| "Glyburide is associated with increased cardiovascular mortality and morbidity in patients with diabetes mellitus undergoing emergent percutaneous coronary intervention after myocardial infarction." | 7.77 | Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study. ( Abildstrom, SZ; Bretler, D; Gislason, GH; Hansen, ML; Hansen, PR; Jørgensen, CH; Norgaard, ML; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2011) |
| "To (a) identify whether hemoglobin A1c remained equivalent in patients converted from glyburide to glipizide, (b) evaluate the prevalence of hypoglycemia during treatment with glyburide or glipizide, (c) compare change in glycemic control for renally impaired versus nonimpaired patients, and (d) analyze dosage conversion ratios selected by providers and measures of patient follow-up after conversion including time until A1c measurement and number of glipizide dose titrations." | 7.77 | Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. ( Cantrell, M; Egge, JA; Shaw, RF; Skoff, RA; Waterbury, NV, 2011) |
| "We compared the vascular effects of rosiglitazone versus glyburide and evaluated asymmetric dimethylarginine (ADMA) and oxidative stress as potential mechanisms associated with changes in vascular health in patients with type 2 diabetes mellitus (T2DM)." | 5.12 | Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. ( Bank, AJ; Gonzalez-Campoy, JM; Kaiser, DR; Kelly, AS; Thelen, AM, 2007) |
| " At presentation, the acute C-peptide response to glucagon in obese DKA patients was lower than in patients with hyperglycemia (P < 0." | 5.08 | Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises. ( Clark, WS; Steen, MT; Umpierrez, GE, 1997) |
| "Glyburide is an improved drug for the management of non-insulin-dependent diabetes mellitus (NIDDM)." | 5.05 | Glyburide (DiaBeta): a new second-generation hypoglycemic agent. ( Krall, LP, 1984) |
| "The effect of glibenclamide and gliquidone on fasting blood glucose, 24-hour urinary glucose excretion, HbA1 concentrations and on the blood glucose and plasma insulin responses to an oral glucose load were investigated in 11 patients with non-insulin-dependent diabetes mellitus." | 5.05 | Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus. ( Groop, L; Nikkilä, K, 1982) |
| "Forty patients with diabetes mellitus and rheumatic disorders (rheumatoid arthritis, osteoarthritis, soft-tissue rheumatism) were included in a double-blind trial with the purpose of investigating whether the concomitant administration of tolmetin and glibenclamide leads to an interaction." | 5.04 | Clinical studies of the interaction between tolmetin and glibenclamide. ( Chlud, K; Kaik, B, 1977) |
| " On the other hand, treatment of obese patients with metformin significantly reduced the incidence of myocardial infarction and of mortality diabetes related." | 4.80 | [Should the occurrence of a first coronary event change the management of diabetes?]. ( Dubois-Laforgue, D; Timsit, J, 2000) |
| "Glyburide is associated with increased cardiovascular mortality and morbidity in patients with diabetes mellitus undergoing emergent percutaneous coronary intervention after myocardial infarction." | 3.77 | Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study. ( Abildstrom, SZ; Bretler, D; Gislason, GH; Hansen, ML; Hansen, PR; Jørgensen, CH; Norgaard, ML; Schramm, TK; Sørensen, R; Torp-Pedersen, C, 2011) |
| "To (a) identify whether hemoglobin A1c remained equivalent in patients converted from glyburide to glipizide, (b) evaluate the prevalence of hypoglycemia during treatment with glyburide or glipizide, (c) compare change in glycemic control for renally impaired versus nonimpaired patients, and (d) analyze dosage conversion ratios selected by providers and measures of patient follow-up after conversion including time until A1c measurement and number of glipizide dose titrations." | 3.77 | Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide. ( Cantrell, M; Egge, JA; Shaw, RF; Skoff, RA; Waterbury, NV, 2011) |
| " FRAE also showed significant increase in serum insulin, body weight and glycogen content in liver and skeletal muscle of STZ-induced diabetic rats while there was significant reduction in the levels of serum triglyceride and total cholesterol." | 3.76 | Antidiabetic effect of Ficus religiosa extract in streptozotocin-induced diabetic rats. ( Jagtap, A; Pandit, R; Phadke, A, 2010) |
| "We describe 3 years follow-up of glyburide therapy in a child with permanent neonatal diabetes mellitus (PND) born to a 19 year-old mother with congenital diabetes mellitus." | 3.74 | Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up. ( Begum-Hasan, J; Brill, H; Polychronakos, C, 2008) |
| " Within 5 hours after administration of a combination of glyburide and metformin, which is used to treat diabetes mellitus in humans, the glucose concentration was within reference limits." | 3.73 | Diabetes mellitus in a domesticated Spanish mustang. ( Johnson, PJ; Kreeger, JM; Messer, NT; Scotty, NC; Wiedmeyer, C, 2005) |
| "Right atrial sections from four patient groups-non-diabetic, insulin-dependent diabetes mellitus (IDDM), non-insulin-dependent diabetes mellitus (NIDDM) receiving glibenclamide, and NIDDM receiving metformin-were subjected to one of the following protocols: aerobic control, simulated ischemia/reoxygenation, ischemic preconditioning before ischemia, and pharmacological preconditioning with alpha 1 agonist phenylephrine, adenosine, the mito-K(ATP) channel opener diazoxide, the protein kinase C (PKC) activator phorbol-12-myristate-13-acetate (PMA), or the p38 mitogen-activated protein kinase (p38MAPK) activator anisomycin." | 3.73 | Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium. ( Fowler, A; Galiñanes, M; Hassouna, A; Loubani, M; Matata, BM; Standen, NB, 2006) |
| "We have studied the pharmacokinetics and pharmacodynamics of glyburide during long-term therapy in 20 patients with type II diabetes mellitus." | 3.68 | The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics. ( Antal, EJ; Jaber, LA; Slaughter, RL; Welshman, IR, 1993) |
| "Glyburide and other sulfonylureas consistently enhance receptor binding in cells from patients with non-insulin-dependent diabetes mellitus, whereas no effects and mixed effects have been demonstrated in cells from patients with insulin-dependent diabetes mellitus and in normal cells, respectively." | 3.67 | Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects. ( Gavin, JR, 1985) |
| "Alterations in plasma branched-chain amino acids (valine, isoleucine and leucine) and alanine have been described in patients with insulin-dependent diabetes mellitus who have poor metabolic control." | 3.66 | Branched-chain amino acids and alanine as indices of the metabolic control in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients. ( Angiolini, A; Ciavarella, A; Forlani, G; Marchesini, G; Pisi, E; Vannini, P; Zoli, M, 1982) |
| " Median frequencies of hypoglycemia and hyperglycemia were less than 5% of routine blood glucose assays and were similar with both dosage forms." | 2.90 | Glibenclamide oral suspension: Suitable and effective in patients with neonatal diabetes. ( Baptiste, A; Beltrand, J; Berdugo, M; Bouazza, N; Boucheron, A; Busiah, K; Djerada, Z; Elie, C; Godot, C; Gozalo, C; Polak, M; Tréluyer, JM, 2019) |
| "Hypotonia was the symptom that responded best." | 2.82 | Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses. ( Beltrand, J; Berdugo, M; Bernardo, WM; de Gouveia Buff Passone, C; Garcin, L; Giani, E; Kariyawasam, D; Polak, M; Vaivre-Douret, L, 2022) |
| "Troglitazone treatment increased serum adiponectin levels nearly threefold." | 2.71 | Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy. ( Aroda, V; Bandukwala, R; Baxi, S; Carter, L; Ciaraldi, TP; Henry, RR; Kong, AP; Mudaliar, SR; Phillips, SA, 2003) |
| "In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks." | 2.69 | Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. ( , 1998) |
| "The differences in AUC, Cmax and CL/f of Gb may be explained by a higher free fraction in the IRF group which would increase Gb metabolic clearance." | 2.69 | Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function. ( Jönsson, A; Melander, A; Rydberg, T; Sterner, G, 1998) |
| " Premixed 70% NPH/30% Regular insulin was taken before supper, and the dosage was adjusted weekly by an algorithm seeking nearly normal fasting glycemia." | 2.67 | Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea. ( Bingham, P; Garrison, C; Hart, J; McDaniel, P; Riddle, M, 1992) |
| " Glibenclamide, Gliquidone, Glusoxepide and placebo were administered in random order with degree dosage adjusted according to degree of severity of diabetes." | 2.65 | [Comparison of glibenclamide, gliquidone, glisoxepide and placebo in maturity onset diabetics of differing degrees of severity (author's transl)]. ( Brändle, J; Irsigler, K; Ogris, E; Regal, H; Steinhardt, T; Zdolsek, I, 1979) |
| " The dosage of sulfinpyrazone used in this trial was well tolerated by all patients and no side effects were observed." | 2.65 | [Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients]. ( Irsigler, K; Kritz, H; Najemnik, C, 1983) |
| "The management of diabetes mellitus is often complicated in patients with advanced cancer." | 2.40 | The management of diabetes in patients with advanced cancer. ( Poulson, J, 1997) |
| "Treatment with glyburide significantly reduced aggregation in response to 10 microM of epinephrine and collagen at 750 microgram/ml." | 2.36 | Sulfonylureas and platelet function. ( Jackson, WP; Jacobs, P; Kernoff, L; Klaff, LJ; Vinik, AI, 1981) |
| "Alloxan 125 mg/kg BW was given intra peritoneal injection on the 8th day to obtain diabetic hypertensive condition." | 1.72 | Blood pressure and blood sugar-lowering effects of purified gambir on diabetic hypertensive Wistar Kyoto rats. ( Abdillah, R; Almahdy, A; Aquista, PG; Armenia, A; Putri, DP; Wahyuni, FS; Zikra, M, 2022) |
| "Hypoglycemia is common in patients with diabetes." | 1.48 | Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury. ( Abdel-Kader, K; Greevy, RA; Griffin, MR; Horner, J; Hung, AM; Ikizler, TA; Matheny, ME; Parr, SK; Perkins, AM; Roumie, CL; Siew, ED; Speroff, T; Wilson, OD, 2018) |
| "Glimepiride, which is a more appropriate sulfonylurea, was suggested as an alternative at order entry." | 1.46 | Implementation and Assessment of an Ambulatory Prescribing Guidance Tool to Improve Patient Safety in the Geriatric Population. ( Bellone, JM; Ruhland, DJ; Wilkes, E, 2017) |
| "The major risk factor for melioidosis, an infectious disease caused by B." | 1.43 | Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione. ( Ato, M; Bancroft, GJ; Kewcharoenwong, C; Lertmemongkolchai, G; Nithichanon, A; Rinchai, D, 2016) |
| "Diabetes mellitus is a metabolic disease characterised by chronically high glucose levels." | 1.42 | Permanent neonatal diabetes mellitus - a case report of a rare cause of diabetes mellitus in East Africa. ( Bahendeka, S; Muhame, MR; Nyangabyaki-Twesigye, C, 2015) |
| "Glyburide was commonly withdrawn after LTCF admission." | 1.42 | Trends in prevalence, incidence and pharmacologic management of diabetes mellitus among seniors newly admitted to long-term care facilities in Saskatchewan between 2003 and 2011. ( Alsabbagh, MW; Blackburn, DF; Champagne, A; Lix, LM; Lu, X; Mansell, K; Shevchuk, Y; Teare, G, 2015) |
| "Metformin use was stable, ranging between 7% and 9% (P = ." | 1.42 | Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011. ( Barnhart, C; Lee, SJ; McClymont, K; Steinman, MA; Stijacic-Cenzer, I, 2015) |
| " They exhibit marked sensitivity to sulfonylurea therapy with current dosing at 0." | 1.40 | Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy. ( Ham, JN; Heptulla, R; Hicks, KA; Kushner, JA, 2014) |
| " Glycaemia values returned to normality only after suspension of escitalopram, despite antidiabetic dosage increase." | 1.39 | A case report on escitalopram-induced hyperglycaemia in a diabetic patient. ( Brasesco, PC; Fucile, C; Leone, S; Martelli, A; Mattioli, F; Milano, G; Zuccoli, ML, 2013) |
| "0% after 8 months of oral glibenclamide treatment with a maintenance dosage of 0." | 1.38 | Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation. ( Chan, AY; Hung, VC; Lam, CW; Lee, CY; Mak, CM; Siu, WK, 2012) |
| "Neonatal diabetes mellitus is rare, may either be transient or permanent, and may be caused by mutations in any of the several different genes." | 1.35 | Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide. ( Bremer, AA; Lustig, RH; Ranadive, S, 2008) |
| " On DOL 25, the glyburide dosage was decreased to 0." | 1.35 | An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus. ( Bremer, AA; Glaser, NS; Loomba-Albrecht, LA; Styne, DM, 2009) |
| "OBJECTIVE To assess if tooth discoloration is a novel side effect of sulfonylurea therapy in patients with permanent neonatal diabetes due to mutations in KCNJ11." | 1.35 | Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect. ( Flanagan, SE; Greeley, SA; Hattersley, AT; Kumaraguru, J; Nuboer, R; Philipson, LH; Rubio-Cabezas, O; Støy, J, 2009) |
| "The R6/2 transgenic mouse model of Huntington's disease (HD) develops a progressive neurological phenotype that involves severe motor and cognitive dysfunctions." | 1.33 | Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents. ( Hunt, MJ; Morton, AJ, 2005) |
| "Some patients with type 2 diabetes present with ketoacidosis and require insulin treatment." | 1.30 | Atypical ketoacidosis in type 2 diabetes. ( Goldberg, RB; Machado, R, 1998) |
| " 68% of all SH-cases did with a dosage of 1-3 mg glibenclamide a day, 28% with 1 mg a day." | 1.28 | [Treatment of newly diagnosed type II diabetic patients with special reference to prescribing glibenclamide in low doses]. ( Bothe, E; Dempe, A; Hanisch, R; Häntzschel, U; Wurlitzer, M, 1989) |
| " Food intake did not influence the bioavailability of a 5 mg dose of glibenclamide." | 1.26 | Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide. ( Melander, A; Sartor, G; Scherstén, B; Wåhlin-Boll, E, 1980) |
| " Food did not affect the bioavailability of any of the four drugs, but delayed Gz absorption." | 1.26 | Kinetics-effect relations of glipizide and other sulfonylureas. ( Melander, A; Sartor, G; Scherstén, B; Wåhlin-Boll, E, 1980) |
| " In accordance with the augmented physiologic insulin release in the morning, a single morning dose of sulfonylureas may be the preferable dosage regimen in the treatment of elderly insulin-independent diabetics of moderate degree." | 1.26 | Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics. ( Groop, L; Harno, K, 1980) |
| "Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy are described in a 61-year-old diabetic patient who presented wit hypoglycaemic coma." | 1.26 | Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy. ( Mills, PR; Patrick, RS; Russell, RI; Wongpaitoon, V, 1981) |
| "Insulin sensitivity has been determined in primary nonobese diabetics and subjects with borderline glucose intolerance by a newly devised technique using glucose, insulin, and somatostatin infusion." | 1.26 | Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin, and somatostatin infusion. ( Harano, Y; Hidaka, H; Izumi, K; Kashiwagi, A; Kobayashi, M; Kosugi, K; Nakano, T; Ohgaku, S; Shigeta, Y; Yasuda, H, 1981) |
| " Irrespective of dosage and mode of administration, addition of glibenclamide to a standardized breakfast, lunch and dinner enhanced plasma IRI concentrations and reduced blood glucose concentrations as compared to administration of meals without the drug." | 1.26 | Improved effect of glibenclamide on administration before breakfast. ( Lundquist, I; Melander, A; Sartor, G; Scherstén, B; Wåhlin-Boll, E, 1982) |
| " A wide interindividual variation in chlorpropamide levels was observed and thus, the prediction of drug concentration was difficult from the dosage alone, despite a statistically significant correlation between the dose per body weight and the serum drug level." | 1.26 | Chlorpropamide and glibenclamide serum concentrations in hospitalized patients. ( Huupponen, R; Saarimaa, H; Viikari, J, 1982) |
| " After changing from the sulfonyl ureas glibornuride, glisoxepide or gliquidone the same mean daily dosage of 1." | 1.26 | [Treatment of adult diabetes with semi-euglucon (author's transl)]. ( Molck, H; Schäfer, D, 1979) |
| " Addition of sulphonylurea induced a left shift in the dose-response relationships in controls and low insulin responders; under these conditions the effect of glibenclamide was more pronounced than that of gliquidone." | 1.26 | Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects. ( Cerasi, E; Efendic, S; Luft, R; Thornqvist, C, 1979) |
| " The changes in weight were similar and both drugs were devoid of serious toxic effects in the dosage prescribed." | 1.26 | Comparative study of glibenclamide & chlorpropamide in newly diagnosed maturity onset diabetics. ( Haider, Z; Obaidullah, S, 1976) |
| " Both extracts exert a significant hypoglycaemic effect by oral route and chronic administration in diabetic rats, but only the extract obtained by exhaustion with hot water displayed an acute hypoglycaemic activity in normal animals." | 1.26 | [Hypoglycaemic activity of centaurea aspera L (author's transl)]. ( Adzet, T; Massó, JL, 1976) |
| " Due to the high frequency of side effects it does not seem to be worthwhile to further investigate the therapeutic effect of MPC in a larger number of patients with different dosage regimens." | 1.25 | [Effect of methylpyrazole-carboxylic acid on carbohydrate and lipid metabolisms in patients with diabetes mellitus]. ( Hassalacher, Ch; Lang, PD; Vollmar, J; Wahl, P, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 259 (62.26) | 18.7374 |
| 1990's | 36 (8.65) | 18.2507 |
| 2000's | 45 (10.82) | 29.6817 |
| 2010's | 66 (15.87) | 24.3611 |
| 2020's | 10 (2.40) | 2.80 |
| Authors | Studies |
|---|---|
| Iqbal, Z | 1 |
| Ali, S | 1 |
| Iqbal, J | 1 |
| Abbas, Q | 1 |
| Qureshi, IZ | 1 |
| Hameed, S | 1 |
| Armenia, A | 1 |
| Wahyuni, FS | 1 |
| Almahdy, A | 1 |
| Abdillah, R | 1 |
| Aquista, PG | 1 |
| Putri, DP | 1 |
| Zikra, M | 1 |
| de Gouveia Buff Passone, C | 1 |
| Giani, E | 1 |
| Vaivre-Douret, L | 2 |
| Kariyawasam, D | 1 |
| Berdugo, M | 3 |
| Garcin, L | 1 |
| Beltrand, J | 3 |
| Bernardo, WM | 1 |
| Polak, M | 4 |
| Walton-Betancourth, S | 1 |
| Ashford, J | 1 |
| Beardsall, K | 1 |
| Gooding, N | 1 |
| Gurnell, EM | 1 |
| Hendriks, E | 1 |
| Hysted, H | 1 |
| Lee, J | 1 |
| Thankamony, A | 1 |
| Tseretopoulou, X | 1 |
| Win, M | 1 |
| Williams, RM | 1 |
| Kibirige, D | 1 |
| Olum, R | 1 |
| Kyazze, AP | 1 |
| Bongomin, F | 1 |
| Sanya, RE | 1 |
| Yadav, A | 3 |
| Kumar, R | 3 |
| Rawat, A | 3 |
| Venkatesan, R | 3 |
| Mancioppi, V | 1 |
| Pozzi, E | 1 |
| Zanetta, S | 1 |
| Missineo, A | 1 |
| Savastio, S | 1 |
| Barbetti, F | 8 |
| Mellone, S | 1 |
| Giordano, M | 1 |
| Rabbone, I | 3 |
| Mott, K | 1 |
| Reichman, ME | 1 |
| Toh, S | 1 |
| Kieswetter, C | 1 |
| Haffenreffer, K | 1 |
| Andrade, SE | 1 |
| Stanik, J | 1 |
| Barak, L | 1 |
| Dankovcikova, A | 1 |
| Valkovicova, T | 1 |
| Skopkova, M | 1 |
| Gasperikova, D | 1 |
| Zubov, A | 1 |
| Muruzheva, Z | 1 |
| Tikhomirova, M | 1 |
| Karpenko, M | 1 |
| Qais, FA | 1 |
| Sarwar, T | 1 |
| Ahmad, I | 1 |
| Khan, RA | 1 |
| Shahzad, SA | 1 |
| Husain, FM | 1 |
| Iafusco, D | 4 |
| Zanfardino, A | 2 |
| Piscopo, A | 1 |
| Casaburo, F | 1 |
| De Nigris, A | 1 |
| Alfiero, S | 1 |
| Russo, G | 1 |
| Arenella, M | 1 |
| Russo, MC | 1 |
| Kylat, RI | 1 |
| Senguttuvan, R | 1 |
| Bader, MY | 1 |
| Amuri, B | 1 |
| Maseho, M | 1 |
| Simbi, L | 1 |
| Okusa, P | 1 |
| Duez, P | 1 |
| Byanga, K | 1 |
| Li, X | 1 |
| Xu, A | 1 |
| Sheng, H | 1 |
| Ting, TH | 1 |
| Mao, X | 1 |
| Huang, X | 1 |
| Jiang, M | 1 |
| Cheng, J | 1 |
| Liu, L | 1 |
| Neumann, U | 1 |
| Bührer, C | 1 |
| Blankenstein, O | 1 |
| Kühnen, P | 1 |
| Raile, K | 1 |
| Kandasamy, B | 1 |
| Shyng, SL | 1 |
| Yildiz, M | 1 |
| Akcay, T | 1 |
| Aydin, B | 1 |
| Akgun, A | 1 |
| Dogan, BB | 1 |
| De Franco, E | 1 |
| Ellard, S | 9 |
| Onal, H | 1 |
| Hung, AM | 1 |
| Siew, ED | 1 |
| Wilson, OD | 1 |
| Perkins, AM | 1 |
| Greevy, RA | 1 |
| Horner, J | 1 |
| Abdel-Kader, K | 1 |
| Parr, SK | 1 |
| Roumie, CL | 1 |
| Griffin, MR | 1 |
| Ikizler, TA | 1 |
| Speroff, T | 1 |
| Matheny, ME | 1 |
| Ioacara, S | 2 |
| Sava, E | 1 |
| Barosan, A | 1 |
| Cojocaru, F | 1 |
| Gutan, A | 1 |
| Fica, S | 2 |
| Emfinger, CH | 1 |
| Yan, Z | 1 |
| Welscher, A | 1 |
| Hung, P | 1 |
| McAllister, W | 1 |
| Hruz, PW | 2 |
| Nichols, CG | 5 |
| Remedi, MS | 3 |
| Cordiner, RLM | 1 |
| Pearson, ER | 3 |
| Baptiste, A | 1 |
| Busiah, K | 2 |
| Bouazza, N | 1 |
| Godot, C | 1 |
| Boucheron, A | 1 |
| Djerada, Z | 2 |
| Gozalo, C | 2 |
| Tréluyer, JM | 2 |
| Elie, C | 2 |
| Khoshakhlagh, AH | 1 |
| Yazdanirad, S | 1 |
| Laal, F | 1 |
| Sarsangi, V | 1 |
| Fendler, W | 1 |
| Pietrzak, I | 2 |
| Brereton, MF | 1 |
| Lahmann, C | 1 |
| Gadzicki, M | 1 |
| Bienkiewicz, M | 1 |
| Drozdz, I | 1 |
| Borowiec, M | 1 |
| Malecki, MT | 3 |
| Ashcroft, FM | 4 |
| Mlynarski, WM | 1 |
| Yang, W | 2 |
| Wei, H | 2 |
| Sang, Y | 2 |
| Kochar, IP | 1 |
| Jindal, R | 1 |
| Kwon, MJ | 1 |
| Chung, HS | 1 |
| Yoon, CS | 1 |
| Lee, EJ | 1 |
| Kim, TK | 1 |
| Lee, SH | 1 |
| Ko, KS | 1 |
| Rhee, BD | 1 |
| Kim, MK | 1 |
| Park, JH | 1 |
| Anguizola, J | 1 |
| Matsuda, R | 1 |
| Barnaby, OS | 1 |
| Hoy, KS | 1 |
| Wa, C | 1 |
| DeBolt, E | 1 |
| Koke, M | 1 |
| Hage, DS | 1 |
| Hicks, KA | 1 |
| Kushner, JA | 1 |
| Heptulla, R | 1 |
| Ham, JN | 1 |
| Shahreen, S | 1 |
| Banik, J | 1 |
| Hafiz, A | 1 |
| Rahman, S | 1 |
| Zaman, AT | 1 |
| Shoyeb, MA | 1 |
| Chowdhury, MH | 1 |
| Rahmatullah, M | 2 |
| Hossain, M | 1 |
| Mahmud, A | 1 |
| Sultana, N | 1 |
| Rahman, SM | 1 |
| Islam, MR | 1 |
| Khatoon, MS | 1 |
| Jahan, S | 1 |
| Islam, F | 1 |
| Philla, KQ | 1 |
| Bauer, AJ | 1 |
| Vogt, KS | 1 |
| Greeley, SA | 3 |
| Zuccoli, ML | 1 |
| Milano, G | 1 |
| Leone, S | 1 |
| Fucile, C | 1 |
| Brasesco, PC | 1 |
| Martelli, A | 1 |
| Mattioli, F | 1 |
| Sastre, J | 1 |
| Luque, A | 1 |
| del Val, F | 1 |
| Aragonés, A | 1 |
| López, J | 1 |
| Abraham, N | 1 |
| Ahamed, A | 1 |
| Unnikrishnan, AG | 1 |
| Kumar, H | 1 |
| Prado-Carro, AM | 1 |
| Calzada-Hernández, J | 1 |
| Marín, S | 1 |
| Cardona-Hernandez, R | 1 |
| Oriola, J | 1 |
| Nicolás, M | 1 |
| Ramon-Krauel, M | 1 |
| Tan, A | 1 |
| Holmes, HM | 1 |
| Kuo, YF | 1 |
| Raji, MA | 1 |
| Goodwin, JS | 1 |
| Oka, H | 1 |
| Suzuki, S | 1 |
| Furuya, A | 1 |
| Matsuo, K | 1 |
| Amamiya, S | 1 |
| Oshima, M | 1 |
| Oka, T | 1 |
| Mukai, T | 1 |
| Okayama, A | 1 |
| Araki, A | 1 |
| Azuma, H | 1 |
| Tanahashi, Y | 1 |
| Salardi, S | 1 |
| Chiari, G | 1 |
| Toni, S | 1 |
| Pesavento, R | 2 |
| Pasquino, B | 1 |
| de Benedictis, A | 1 |
| Maltoni, G | 1 |
| Colombo, C | 4 |
| Russo, L | 2 |
| Massa, O | 1 |
| Sudano, M | 1 |
| Cadario, F | 2 |
| Porta, M | 1 |
| Myngheer, N | 1 |
| Allegaert, K | 1 |
| Hattersley, A | 1 |
| McDonald, T | 1 |
| Kramer, H | 1 |
| Verhaeghe, J | 1 |
| Mathieu, C | 1 |
| Casteels, K | 1 |
| Alsabbagh, MW | 1 |
| Mansell, K | 1 |
| Lix, LM | 1 |
| Teare, G | 1 |
| Shevchuk, Y | 1 |
| Lu, X | 1 |
| Champagne, A | 1 |
| Blackburn, DF | 1 |
| Marshall, BA | 2 |
| Green, RP | 1 |
| Wambach, J | 1 |
| White, NH | 2 |
| Douros, A | 1 |
| Ebert, N | 1 |
| Jakob, O | 1 |
| Martus, P | 1 |
| Kreutz, R | 1 |
| Schaeffner, E | 1 |
| Thurber, BW | 1 |
| Carmody, D | 1 |
| Tadie, EC | 1 |
| Pastore, AN | 1 |
| Dickens, JT | 1 |
| Wroblewski, KE | 1 |
| Naylor, RN | 1 |
| Philipson, LH | 2 |
| Lee, SJ | 1 |
| Stijacic-Cenzer, I | 1 |
| Barnhart, C | 1 |
| McClymont, K | 1 |
| Steinman, MA | 1 |
| Lau, E | 1 |
| Correia, C | 1 |
| Freitas, P | 1 |
| Nogueira, C | 1 |
| Costa, M | 1 |
| Saavedra, A | 1 |
| Costa, C | 1 |
| Carvalho, D | 1 |
| Fontoura, M | 1 |
| Fournier, E | 1 |
| Boddaert, N | 1 |
| Bahi-Buisson, N | 1 |
| Vera, M | 1 |
| Bui-Quoc, E | 1 |
| Ingster-Moati, I | 1 |
| Simon, A | 1 |
| Flechtner, I | 2 |
| Scharfmann, R | 1 |
| Cavé, H | 1 |
| Marigliano, M | 1 |
| Bonfanti, R | 2 |
| Piccinno, E | 1 |
| Ortolani, F | 1 |
| Ignaccolo, G | 1 |
| Maffeis, C | 1 |
| Confetto, S | 1 |
| Cerutti, F | 1 |
| Nyangabyaki-Twesigye, C | 1 |
| Muhame, MR | 1 |
| Bahendeka, S | 1 |
| Hashimoto, Y | 1 |
| Dateki, S | 1 |
| Hirose, M | 1 |
| Satomura, K | 1 |
| Sawada, H | 1 |
| Mizuno, H | 1 |
| Sugihara, S | 1 |
| Maruyama, K | 1 |
| Urakami, T | 2 |
| Sugawara, H | 1 |
| Shirai, K | 1 |
| Yorifuji, T | 2 |
| Kewcharoenwong, C | 1 |
| Rinchai, D | 1 |
| Nithichanon, A | 1 |
| Bancroft, GJ | 1 |
| Ato, M | 1 |
| Lertmemongkolchai, G | 1 |
| Flanagan, S | 1 |
| Fröhlich-Reiterer, E | 1 |
| Goland, R | 1 |
| Zheng, M | 1 |
| Li, LZ | 1 |
| Jiang, ZA | 1 |
| Li, LH | 1 |
| Feng, YG | 1 |
| Fu, XH | 1 |
| Ruhland, DJ | 1 |
| Bellone, JM | 1 |
| Wilkes, E | 1 |
| Turkkahraman, D | 1 |
| Bircan, I | 1 |
| Tribble, ND | 1 |
| Akçurin, S | 1 |
| Gloyn, AL | 1 |
| Tayek, J | 1 |
| Ye, Y | 1 |
| Lin, Y | 1 |
| Perez-Polo, JR | 1 |
| Birnbaum, Y | 1 |
| Begum-Hasan, J | 1 |
| Polychronakos, C | 1 |
| Brill, H | 1 |
| Della Manna, T | 1 |
| Battistim, C | 1 |
| Radonsky, V | 1 |
| Savoldelli, RD | 1 |
| Damiani, D | 1 |
| Kok, F | 1 |
| Hattersley, AT | 6 |
| Reis, AF | 1 |
| Delvecchio, M | 2 |
| Zecchino, C | 2 |
| Faienza, MF | 2 |
| Acquafredda, A | 1 |
| Cavallo, L | 2 |
| Kumaraguru, J | 1 |
| Flanagan, SE | 4 |
| Nuboer, R | 2 |
| Støy, J | 1 |
| Rubio-Cabezas, O | 1 |
| Loomba-Albrecht, LA | 1 |
| Glaser, NS | 1 |
| Styne, DM | 1 |
| Bremer, AA | 2 |
| Nagashima, K | 1 |
| Inagaki, N | 1 |
| Martín-Frías, M | 1 |
| Colino, E | 1 |
| Pérez de Nanclares, G | 1 |
| Alonso, M | 1 |
| Ros, P | 1 |
| Barrio, R | 1 |
| Wambach, JA | 1 |
| Koster, JC | 1 |
| Aragão, DM | 1 |
| Guarize, L | 1 |
| Lanini, J | 1 |
| da Costa, JC | 1 |
| Garcia, RM | 1 |
| Scio, E | 1 |
| Pandit, R | 1 |
| Phadke, A | 1 |
| Jagtap, A | 1 |
| Yeo, JL | 1 |
| Tan, BT | 1 |
| Achike, FI | 1 |
| Jørgensen, CH | 2 |
| Gislason, GH | 2 |
| Bretler, D | 1 |
| Sørensen, R | 2 |
| Norgaard, ML | 2 |
| Hansen, ML | 1 |
| Schramm, TK | 1 |
| Abildstrom, SZ | 1 |
| Torp-Pedersen, C | 2 |
| Hansen, PR | 2 |
| Sutin, DG | 1 |
| Ješić, MM | 1 |
| Ješić, MD | 1 |
| Maglajlić, S | 1 |
| Sajić, S | 1 |
| Necić, S | 1 |
| Holstein, A | 1 |
| Agapova, SE | 1 |
| Vyas, AK | 1 |
| Bizzarri, C | 1 |
| Tonini, G | 1 |
| Tumini, S | 1 |
| Cauvin, V | 1 |
| Andersson, C | 1 |
| Vaag, A | 1 |
| Mérie, C | 1 |
| Olesen, JB | 1 |
| Weeke, P | 1 |
| Schmiegelow, M | 1 |
| Køber, L | 1 |
| Skoff, RA | 1 |
| Waterbury, NV | 1 |
| Shaw, RF | 1 |
| Egge, JA | 1 |
| Cantrell, M | 1 |
| Mak, CM | 1 |
| Lee, CY | 1 |
| Lam, CW | 1 |
| Siu, WK | 1 |
| Hung, VC | 1 |
| Chan, AY | 1 |
| Siklar, Z | 1 |
| Okulu, E | 1 |
| Berberoğlu, M | 1 |
| Young, E | 1 |
| Savaş Erdeve, S | 1 |
| Mungan, IA | 1 |
| Hacihamdioğlu, B | 1 |
| Erdeve, O | 1 |
| Arsan, S | 1 |
| Oçal, G | 1 |
| Nagano, N | 1 |
| Mine, Y | 1 |
| Watanabe, H | 1 |
| Yoshida, A | 1 |
| Suzuki, J | 1 |
| Saito, H | 1 |
| Ishige, M | 1 |
| Takahashi, S | 1 |
| Mugishima, H | 1 |
| Guidoni, CM | 1 |
| Borges, AP | 1 |
| Freitas, Od | 1 |
| Pereira, LR | 1 |
| Battaglia, D | 1 |
| Lin, YW | 1 |
| Brogna, C | 1 |
| Crinò, A | 1 |
| Grasso, V | 1 |
| Mozzi, AF | 1 |
| Spera, S | 1 |
| Ricci, S | 1 |
| Mercuri, E | 1 |
| Shah, B | 1 |
| Breidbart, E | 1 |
| Pawelczak, M | 1 |
| Lam, L | 1 |
| Kessler, M | 1 |
| Franklin, B | 1 |
| Dupont, J | 1 |
| Pereira, C | 1 |
| Medeira, A | 1 |
| Duarte, R | 1 |
| Sampaio, L | 1 |
| Khurana, D | 1 |
| Contreras, M | 1 |
| Malhotra, N | 1 |
| Bargman, R | 1 |
| Noda, M | 1 |
| Yamashita, S | 1 |
| Takahashi, N | 1 |
| Eto, K | 1 |
| Shen, LM | 1 |
| Izumi, K | 2 |
| Daniel, S | 1 |
| Tsubamoto, Y | 1 |
| Nemoto, T | 1 |
| Iino, M | 1 |
| Kasai, H | 1 |
| Sharp, GW | 1 |
| Kadowaki, T | 1 |
| Hauser, D | 1 |
| Buckelman, A | 1 |
| Katz, H | 1 |
| Rechtman, E | 1 |
| Klayman, G | 1 |
| Pollack, A | 1 |
| Miura, H | 1 |
| Wachtel, RE | 1 |
| Loberiza, FR | 1 |
| Saito, T | 1 |
| Miura, M | 1 |
| Nicolosi, AC | 1 |
| Gutterman, DD | 1 |
| Phillips, SA | 1 |
| Ciaraldi, TP | 1 |
| Kong, AP | 1 |
| Bandukwala, R | 1 |
| Aroda, V | 1 |
| Carter, L | 1 |
| Baxi, S | 1 |
| Mudaliar, SR | 1 |
| Henry, RR | 1 |
| Bingham, E | 1 |
| Hopkins, D | 1 |
| Pernet, A | 1 |
| Reid, H | 1 |
| Macdonald, IA | 1 |
| Amiel, SA | 2 |
| Aronson, D | 1 |
| Mittleman, MA | 1 |
| Burger, AJ | 1 |
| Mori, Y | 2 |
| Komiya, H | 1 |
| Kurokawa, N | 1 |
| Tajima, N | 1 |
| Hussain, Z | 1 |
| Waheed, A | 1 |
| Qureshi, RA | 1 |
| Burdi, DK | 1 |
| Verspohl, EJ | 1 |
| Khan, N | 1 |
| Hasan, M | 1 |
| Faglia, E | 1 |
| Zung, A | 1 |
| Glaser, B | 2 |
| Nimri, R | 1 |
| Zadik, Z | 1 |
| Johnson, PJ | 1 |
| Scotty, NC | 1 |
| Wiedmeyer, C | 1 |
| Messer, NT | 1 |
| Kreeger, JM | 1 |
| Schneider, S | 1 |
| Feilen, PJ | 1 |
| Schreckenberger, M | 1 |
| Schwanstecher, M | 1 |
| Schwanstecher, C | 1 |
| Buchholz, HG | 1 |
| Thews, O | 1 |
| Oberholzer, K | 1 |
| Korobeynikov, A | 1 |
| Bauman, A | 1 |
| Comagic, S | 1 |
| Piel, M | 1 |
| Schirrmacher, E | 1 |
| Shiue, CY | 1 |
| Alavi, AA | 1 |
| Bartenstein, P | 1 |
| Rösch, F | 1 |
| Weber, MM | 1 |
| Klein, HH | 1 |
| Schirrmacher, R | 1 |
| Hunt, MJ | 1 |
| Morton, AJ | 1 |
| Hassouna, A | 1 |
| Loubani, M | 1 |
| Matata, BM | 1 |
| Fowler, A | 1 |
| Standen, NB | 1 |
| Galiñanes, M | 1 |
| Njølstad, PR | 1 |
| Larkin, B | 1 |
| Klimes, I | 1 |
| Codner, E | 2 |
| Iotova, V | 1 |
| Slingerland, AS | 2 |
| Shield, J | 1 |
| Robert, JJ | 1 |
| Holst, JJ | 1 |
| Clark, PM | 1 |
| Søvik, O | 1 |
| Sperling, MA | 1 |
| Hadders-Algra, M | 1 |
| Bruining, GJ | 1 |
| Ugarte, F | 1 |
| García, H | 1 |
| Vidal, T | 1 |
| Landau, Z | 1 |
| Wainstein, J | 1 |
| Hanukoglu, A | 1 |
| Tuval, M | 1 |
| Lavie, J | 1 |
| Shimomura, K | 1 |
| Hörster, F | 1 |
| de Wet, H | 1 |
| Wolf, NI | 1 |
| Ashcroft, F | 1 |
| Ebinger, F | 1 |
| Kim, MS | 1 |
| Kim, SY | 1 |
| Kim, GH | 1 |
| Yoo, HW | 1 |
| Lee, DW | 1 |
| Lee, DY | 1 |
| Mlynarski, W | 1 |
| Tarasov, AI | 1 |
| Gach, A | 1 |
| Girard, CA | 1 |
| Zubcevic, L | 1 |
| Kusmierek, J | 1 |
| Klupa, T | 1 |
| Kelly, AS | 1 |
| Thelen, AM | 1 |
| Kaiser, DR | 1 |
| Gonzalez-Campoy, JM | 1 |
| Bank, AJ | 1 |
| Ushakova, EA | 1 |
| Ranadive, S | 1 |
| Lustig, RH | 1 |
| Juan, O | 1 |
| Esteban, E | 1 |
| Sotillo, J | 1 |
| Alberola, V | 1 |
| Pan, F | 1 |
| Chernew, ME | 1 |
| Fendrick, AM | 1 |
| Harano, Y | 1 |
| Ohgaku, S | 1 |
| Kosugi, K | 1 |
| Yasuda, H | 1 |
| Nakano, T | 1 |
| Kobayashi, M | 1 |
| Hidaka, H | 1 |
| Kashiwagi, A | 1 |
| Shigeta, Y | 1 |
| Bretzke, G | 1 |
| Oltmanns, D | 1 |
| Schwab, J | 1 |
| Finn, H | 1 |
| Haller, H | 2 |
| Shima, K | 1 |
| Tanaka, A | 1 |
| Ikegami, H | 1 |
| Tabata, M | 1 |
| Sawazaki, N | 1 |
| Kumahara, Y | 1 |
| Klimm, HD | 1 |
| Vollmar, J | 3 |
| Bräuning, C | 1 |
| Kolterman, OG | 1 |
| Prince, MJ | 1 |
| Olefsky, JM | 1 |
| Kritz, H | 1 |
| Najemnik, C | 1 |
| Irsigler, K | 2 |
| Breier, C | 2 |
| Lisch, HJ | 3 |
| Drexel, H | 1 |
| Sailer, S | 3 |
| Chiasson, JL | 1 |
| Hamet, P | 1 |
| Krall, LP | 2 |
| Tattersall, RB | 2 |
| Tamai, T | 2 |
| Sartor, G | 3 |
| Melander, A | 4 |
| Scherstén, B | 3 |
| Wåhlin-Boll, E | 3 |
| Kuzuya, K | 1 |
| Lunetta, M | 3 |
| Presti, C | 2 |
| Mughini, MT | 2 |
| Mughini, L | 3 |
| Paisey, RB | 1 |
| Harkness, J | 1 |
| Hartog, M | 1 |
| Chadwick, T | 1 |
| Ingelmo, M | 1 |
| Vivancos, J | 1 |
| Bruguera, M | 1 |
| Sierra, J | 1 |
| Balcells, A | 1 |
| Burke, BJ | 1 |
| Sherriff, RJ | 1 |
| Groop, L | 3 |
| Harno, K | 1 |
| Owens, DR | 2 |
| Biggs, PI | 3 |
| Shetty, KJ | 1 |
| Wragg, KG | 2 |
| Coetzee, EJ | 2 |
| Jackson, WP | 5 |
| Leroith, D | 1 |
| Shapiro, M | 1 |
| Luboshitsky, R | 1 |
| Spitz, IM | 1 |
| Skillman, TG | 1 |
| Feldman, JM | 1 |
| Mourits-Andersen, T | 1 |
| Ditzel, J | 1 |
| Sönksen, PH | 1 |
| Lowy, C | 1 |
| Perkins, JR | 1 |
| West, TE | 1 |
| Lohmann, D | 2 |
| Verlohren, HJ | 3 |
| Klaff, LJ | 2 |
| Kernoff, L | 2 |
| Vinik, AI | 2 |
| Jacobs, P | 2 |
| Ward, EA | 1 |
| Ward, GM | 1 |
| Turner, RC | 1 |
| Fonseca, VA | 1 |
| Wongpaitoon, V | 1 |
| Mills, PR | 1 |
| Russell, RI | 1 |
| Patrick, RS | 1 |
| Traumann, KJ | 1 |
| Hösl, W | 1 |
| Grom, E | 1 |
| Wittemann, G | 1 |
| Fukumoto, Y | 1 |
| Ichihara, K | 2 |
| Nonaka, K | 3 |
| Tarui, S | 2 |
| Hiramatsu, K | 1 |
| Nozaki, H | 1 |
| Arimori, S | 1 |
| Nakai, T | 1 |
| Yamada, S | 1 |
| Kobayashi, T | 1 |
| Hayashi, T | 1 |
| Kutsumi, Y | 1 |
| Oida, K | 1 |
| Takeda, R | 1 |
| Zaman, R | 1 |
| Kendall, MJ | 1 |
| Nikkilä, K | 1 |
| Lundquist, I | 1 |
| Vannini, P | 1 |
| Marchesini, G | 1 |
| Forlani, G | 1 |
| Angiolini, A | 1 |
| Ciavarella, A | 1 |
| Zoli, M | 1 |
| Pisi, E | 1 |
| Gastpar, H | 1 |
| Weissgerber, PW | 1 |
| Enzmann, F | 1 |
| Zoltobrocki, M | 2 |
| Ratzmann, KP | 1 |
| Witt, S | 1 |
| Schulz, B | 1 |
| Jahr, D | 1 |
| Heinke, P | 1 |
| Janka, HU | 1 |
| Standl, A | 1 |
| Holler, HD | 1 |
| Mehnert, H | 2 |
| Hamelbeck, H | 1 |
| Klein, W | 1 |
| Schöffling, K | 11 |
| Huupponen, R | 1 |
| Viikari, J | 1 |
| Saarimaa, H | 1 |
| Tsukiyama, K | 1 |
| DeFronzo, RA | 1 |
| Goodman, AM | 1 |
| Ashcroft, SJ | 1 |
| Otabe, S | 1 |
| Sakura, H | 1 |
| Shimokawa, K | 1 |
| Kadowaki, H | 1 |
| Yasuda, K | 1 |
| Hagura, R | 1 |
| Akanuma, Y | 1 |
| Yazaki, Y | 1 |
| Ayani Almagia, I | 1 |
| Muñoz Muñoz, MJ | 1 |
| Hernández Macías, C | 1 |
| Gutiérrez Herrador, G | 1 |
| Rodríguez Sasiain, JM | 1 |
| Jaber, LA | 1 |
| Antal, EJ | 1 |
| Slaughter, RL | 1 |
| Welshman, IR | 1 |
| Pelikánová, T | 1 |
| Kohout, M | 1 |
| Válek, J | 1 |
| Kazdová, L | 1 |
| Base, J | 1 |
| Kumar, S | 1 |
| Boulton, AJ | 1 |
| Miller, JL | 1 |
| Salman, K | 1 |
| Shulman, LH | 1 |
| Rose, LI | 1 |
| Tammelleo, AD | 1 |
| Jones, TW | 1 |
| Boulware, SD | 1 |
| Caprio, S | 1 |
| Merkel, P | 1 |
| Pearson, HA | 1 |
| Sherwin, RS | 1 |
| Tamborlane, WV | 1 |
| Tokuyama, Y | 1 |
| Fan, Z | 1 |
| Furuta, H | 1 |
| Makielski, JC | 1 |
| Polonsky, KS | 1 |
| Bell, GI | 1 |
| Yano, H | 1 |
| Islam, SI | 1 |
| Masuda, QN | 1 |
| Bolaji, OO | 1 |
| Shaheen, FM | 1 |
| Sheikh, IA | 1 |
| Umpierrez, GE | 1 |
| Clark, WS | 1 |
| Steen, MT | 1 |
| Poulson, J | 1 |
| Cleveland, JC | 1 |
| Meldrum, DR | 1 |
| Cain, BS | 1 |
| Banerjee, A | 1 |
| Harken, AH | 1 |
| Goldberg, RB | 1 |
| Machado, R | 1 |
| Jönsson, A | 1 |
| Rydberg, T | 1 |
| Sterner, G | 1 |
| Chan, TY | 1 |
| Hanefeld, M | 1 |
| Temelkova-Kurktschiev, T | 1 |
| Raúl Ariza-Andraca, C | 1 |
| Barile-Fabris, LA | 1 |
| Frati-Munari, AC | 1 |
| Baltazár-Montufar, P | 1 |
| Mooradian, AD | 1 |
| Thurman, JE | 1 |
| Ladis, V | 1 |
| Theodorides, C | 1 |
| Palamidou, F | 1 |
| Frissiras, S | 1 |
| Berdousi, H | 1 |
| Kattamis, C | 1 |
| Miossec, P | 1 |
| Lormeau, B | 1 |
| Valensi, P | 1 |
| Arthuis, F | 1 |
| Amouroux, J | 1 |
| Attali, JR | 1 |
| Laghmich, A | 1 |
| Ladrière, L | 1 |
| Malaisse-Lagae, F | 1 |
| Malaisse, WJ | 1 |
| Sharma, A | 1 |
| Kharb, S | 1 |
| Chugh, SN | 1 |
| Kakkar, R | 1 |
| Singh, GP | 1 |
| Rigalleau, V | 1 |
| Gatta, B | 1 |
| Bonnaud, S | 1 |
| Masson, M | 1 |
| Bourgeois, ML | 1 |
| Vergnot, V | 1 |
| Gin, H | 1 |
| Timsit, J | 1 |
| Dubois-Laforgue, D | 1 |
| Fedorchenko, IuL | 1 |
| Goncharova, EN | 1 |
| Koblova, NM | 1 |
| Gupta, R | 1 |
| Mittal, A | 1 |
| Bhatnagar, LK | 1 |
| Bansal, NK | 1 |
| Rosenecker, J | 1 |
| Eichler, I | 1 |
| Bärmeier, H | 1 |
| von der Hardt, H | 1 |
| Efanov, AM | 1 |
| Appelskog, IB | 1 |
| Abdel-Halim, SM | 1 |
| Khan, A | 1 |
| Bränström, R | 1 |
| Larsson, O | 1 |
| Ostenson, CG | 1 |
| Mest, HJ | 1 |
| Berggren, PO | 1 |
| Efendic, S | 2 |
| Zaitsev, SV | 1 |
| Knick, B | 1 |
| Thomas, L | 1 |
| Bauer, G | 1 |
| Luntz, GR | 2 |
| Clarke, BF | 2 |
| Campbell, IW | 2 |
| Bogie, W | 1 |
| George, J | 1 |
| Crane, CW | 1 |
| Tirelli, F | 1 |
| Bonetti, A | 1 |
| D'Antuono, A | 1 |
| Magnati, G | 1 |
| Pugnoli, C | 1 |
| Strata, A | 1 |
| Zuliani, U | 1 |
| Pagano, G | 1 |
| Diana, A | 1 |
| Pisu, E | 1 |
| Trovati, M | 1 |
| Pitucco, G | 2 |
| Caputo, V | 2 |
| Santucci, A | 2 |
| Daniele, E | 1 |
| De Mattia, G | 3 |
| De Angelis, A | 1 |
| Ellorhaoui, M | 1 |
| Pohl, A | 2 |
| Reddi, AS | 1 |
| Oppermann, W | 1 |
| Patel, DG | 1 |
| Ehrenreich, T | 1 |
| Camerini-Davalos, RA | 1 |
| Nattrass, M | 2 |
| Hinks, L | 2 |
| Smythe, P | 1 |
| Todd, PG | 2 |
| Alberti, KG | 3 |
| Uccella, R | 2 |
| Mascetti, P | 1 |
| Mascetti, R | 1 |
| Sampietro, M | 1 |
| Beck-Nielsen, H | 2 |
| Pedersen, O | 2 |
| Lindskov, HO | 1 |
| Schäfer, D | 1 |
| Molck, H | 1 |
| Kawashima, K | 1 |
| Kuzuya, T | 1 |
| Matsuda, A | 1 |
| Cerasi, E | 1 |
| Thornqvist, C | 1 |
| Luft, R | 1 |
| Shetty, KT | 1 |
| Davies, CD | 1 |
| Ogris, E | 1 |
| Steinhardt, T | 1 |
| Brändle, J | 1 |
| Regal, H | 1 |
| Zdolsek, I | 1 |
| Hayes, JR | 1 |
| Callaghan, S | 1 |
| Grant, AP | 1 |
| Blohmé, G | 2 |
| Waldenström, J | 1 |
| Dudczak, R | 1 |
| Waldhäusl, W | 1 |
| Malan, E | 1 |
| Mogensen, EF | 2 |
| Worm, J | 2 |
| Mikkelsen, BO | 2 |
| Guirgis, FK | 1 |
| Ghanem, MH | 1 |
| Abdel-Hay, MM | 1 |
| Happ, J | 2 |
| Nest, E | 2 |
| Fröhlich, A | 2 |
| Beyer, J | 9 |
| Haslbeck, M | 1 |
| Simons, LA | 1 |
| Myant, NB | 1 |
| Codaccioni, JL | 1 |
| Fontaine, G | 1 |
| Foy, JM | 1 |
| Lucas, PD | 1 |
| Moncada Lorenzo, E | 1 |
| Garcia, RV | 1 |
| Barberia Layana, JJ | 1 |
| Morant Ciscard, JA | 1 |
| Calleja Canelas, A | 1 |
| Balant, L | 1 |
| Zahnd, GR | 1 |
| Weber, F | 1 |
| Fabre, J | 2 |
| Shaw, KM | 2 |
| Bulpitt, CJ | 2 |
| Bloom, A | 3 |
| Flenker, I | 1 |
| Neuhausen, P | 1 |
| Ricken, D | 1 |
| Sabin, G | 1 |
| Lloyd, B | 1 |
| Palmieri, G | 1 |
| Alkabes, M | 1 |
| Barjot, B | 1 |
| Torri, A | 2 |
| Zanni, A | 2 |
| Roncaia, R | 1 |
| Di Saverio, S | 1 |
| Gero, L | 1 |
| Baranyi, E | 2 |
| Steczek, K | 1 |
| Petrányi, G | 1 |
| Tamás, G | 2 |
| Chlud, K | 1 |
| Kaik, B | 1 |
| de Looff, AJ | 1 |
| Beischer, W | 4 |
| Raptis, S | 8 |
| Keller, L | 4 |
| Maas, M | 1 |
| Beischer, B | 2 |
| Feilen, K | 1 |
| Pfeiffer, EF | 8 |
| Giulietti, M | 1 |
| Kerner, W | 3 |
| Birk, W | 1 |
| Schmidt, HA | 1 |
| Petrides, P | 1 |
| Radó, J | 1 |
| Szende, L | 1 |
| Borbély, L | 1 |
| Marosi, J | 1 |
| Juhos, E | 1 |
| Takó, J | 1 |
| Giangrandi, E | 1 |
| Scaroina, F | 1 |
| Tommasini-Degna, C | 1 |
| Tandon, RK | 1 |
| Srivastava, LM | 1 |
| Pandey, SC | 1 |
| Lang, PD | 1 |
| Wahl, P | 2 |
| Hassalacher, Ch | 1 |
| Soler, NG | 1 |
| Bennett, MA | 1 |
| Pentecost, BL | 1 |
| Fitzgerald, MG | 1 |
| Malins, JM | 1 |
| Zilker, T | 3 |
| Ermler, R | 4 |
| Henderkott, U | 1 |
| Bottermann, P | 4 |
| Ziler, T | 1 |
| Waldthaler, A | 1 |
| Sorge, F | 1 |
| Neuhaus, GA | 1 |
| Willms, B | 1 |
| Schmidt, R | 1 |
| Pohl, C | 1 |
| Krappe, U | 1 |
| Vasiukova, EA | 2 |
| Granovskaia-Tsvetkova, AM | 2 |
| Bandisode, MS | 1 |
| Boshell, BR | 1 |
| Watson, WA | 1 |
| Petrie, JC | 1 |
| Galloway, DB | 1 |
| Bullock, I | 1 |
| Gilbert, JC | 1 |
| Haider, Z | 1 |
| Obaidullah, S | 1 |
| Kränzlin, T | 1 |
| Schweigart, U | 1 |
| Pogátsa, G | 1 |
| De Vigan, C | 1 |
| Delporte, MP | 1 |
| Thomas, M | 1 |
| Perrault, M | 1 |
| Andreev, D | 1 |
| Pampulov, L | 1 |
| Kränzlin, H | 1 |
| Baumeister, G | 1 |
| Zierden, E | 1 |
| Wagner, H | 1 |
| Stahl, M | 1 |
| Pittera, A | 1 |
| Ruvolo, F | 1 |
| Di Blasi, F | 1 |
| Fedele, D | 1 |
| Tiengo, A | 1 |
| Muggeo, M | 1 |
| Garotti, C | 1 |
| Crepaldi, G | 1 |
| Brunová, E | 1 |
| Pagliano, FM | 1 |
| Bombara, R | 1 |
| Giraldi, B | 1 |
| Visca, U | 1 |
| Wildenhoff, KE | 1 |
| Heinze, E | 1 |
| Béla, P | 1 |
| Miklós, G | 1 |
| Massó, JL | 1 |
| Adzet, T | 1 |
| Ferlito, S | 1 |
| Mangiagli, P | 1 |
| Federico, M | 1 |
| Sauer, H | 2 |
| Schneider, B | 1 |
| Tutin, M | 1 |
| Trischitta, V | 1 |
| Italia, S | 1 |
| Mazzarino, S | 1 |
| Buscema, M | 1 |
| Rabuazzo, AM | 1 |
| Sangiorgio, L | 1 |
| Squatrito, S | 1 |
| Vigneri, R | 1 |
| Peters, AL | 1 |
| Davidson, MB | 1 |
| Laurenti, O | 1 |
| Bravi, MC | 1 |
| Faldetta, MC | 1 |
| Riddle, M | 1 |
| Hart, J | 1 |
| Bingham, P | 1 |
| Garrison, C | 1 |
| McDaniel, P | 1 |
| Bhatia, RS | 1 |
| Keller, JT | 1 |
| Narang, NK | 1 |
| Meratwal, S | 1 |
| Jain, PC | 1 |
| Vlahos, WD | 1 |
| Seemayer, TA | 1 |
| Yale, JF | 1 |
| Doi, K | 1 |
| Luco, CF | 1 |
| Valenzuela, RF | 1 |
| Häntzschel, U | 1 |
| Wurlitzer, M | 1 |
| Hanisch, R | 1 |
| Bothe, E | 1 |
| Dempe, A | 1 |
| Halloran, SP | 1 |
| Marks, V | 1 |
| Behn, A | 1 |
| Wright, J | 1 |
| Cottez, ML | 1 |
| Ikeda, T | 1 |
| Ito, Y | 1 |
| Murakami, I | 1 |
| Mokuda, O | 1 |
| Tokumori, Y | 1 |
| Tominaga, M | 1 |
| Mashiba, H | 1 |
| Born, P | 1 |
| Neuhaus, H | 1 |
| Eimiller, A | 1 |
| Paul, F | 1 |
| Emilsson, H | 1 |
| Sjöberg, S | 1 |
| Svedner, M | 1 |
| Christenson, I | 1 |
| Goh, CL | 1 |
| Welle, S | 1 |
| Nair, KS | 1 |
| Lockwood, D | 1 |
| Danneberg, G | 1 |
| Brunner, E | 1 |
| Bierwolf, B | 1 |
| Epishin, AV | 1 |
| Likhatskaia, VA | 1 |
| Iakimishina, MM | 1 |
| Baranenko, LP | 1 |
| Salo, S | 1 |
| Hother-Nielsen, O | 1 |
| Schmitz, O | 1 |
| Andersen, PH | 1 |
| Nakahara, Y | 2 |
| Matsuyama, E | 1 |
| Tamura, T | 1 |
| Zecca, L | 1 |
| Trivulzio, S | 1 |
| Pinelli, A | 1 |
| Colombo, R | 1 |
| Tofanetti, O | 1 |
| Gavin, JR | 1 |
| Kostner, GM | 1 |
| Schernthaner, G | 1 |
| Breidahl, HD | 1 |
| Reinwein, D | 1 |
| Robinson, R | 1 |
| Haupt, E | 7 |
| Cordes, U | 2 |
| Kutschera, J | 1 |
| Piroska, E | 1 |
| Ahuja, MM | 3 |
| Gupta, SP | 2 |
| Sehgel, VK | 1 |
| Köberich, W | 2 |
| Rosak, C | 1 |
| Van Mieghem, W | 1 |
| Keller, P | 1 |
| Rastogi, GK | 2 |
| Dash, RJ | 2 |
| Sinha, MK | 1 |
| Schilling, I | 1 |
| Bruns, W | 1 |
| Mehnert, E | 1 |
| Mohnike, A | 1 |
| Jutzi, E | 1 |
| Schliack, V | 1 |
| Schulze, J | 1 |
| Böhm, W | 1 |
| Ram, BK | 1 |
| Sinha, SM | 1 |
| Rothenbuchner, G | 1 |
| Fähndrich, W | 1 |
| Liebermeister, H | 1 |
| Schmitt, H | 1 |
| Daweke, H | 1 |
| De Leeuw, I | 1 |
| De Baere, H | 1 |
| Decraene, P | 1 |
| Lemmens, P | 1 |
| Verhaegen, H | 1 |
| Stowers, JM | 1 |
| Jansen, W | 1 |
| Pisarskaia, IV | 1 |
| Sharova, IuA | 1 |
| Ravina, A | 1 |
| Kain, T | 1 |
| Schröder, KE | 2 |
| Petzoldt, R | 1 |
| Solanki, SV | 1 |
| Yajnik, VH | 1 |
| Shah, SS | 1 |
| Shah, DP | 1 |
| Baranyi, A | 1 |
| Radványi, A | 1 |
| Okajima, J | 1 |
| Tripathy, BB | 1 |
| Kar, BC | 1 |
| Tej, SC | 1 |
| Panda, NC | 1 |
| Parija, CR | 1 |
| Calì, V | 1 |
| Sgroi, C | 1 |
| Specchia, G | 1 |
| Tenconi, M | 1 |
| Ray, M | 1 |
| Degna, CT | 1 |
| Ceruso, D | 1 |
| Squadrito, G | 1 |
| Emanuele, M | 1 |
| Quartarone, M | 1 |
| Bellinghieri, G | 1 |
| Lopatyński, J | 1 |
| Hanzlik, J | 1 |
| Fijalkowska, A | 1 |
| Postiglione, F | 1 |
| Verdoliva, A | 1 |
| Schiraldi, F | 1 |
| Ewing, DJ | 1 |
| Beveridge, GW | 1 |
| MacDonald, MK | 1 |
| Polosa, P | 1 |
| Heine, P | 2 |
| Kewitz, H | 3 |
| Schnapperelle, U | 1 |
| Beringer, A | 1 |
| Althoff, PH | 1 |
| Gervasini, A | 1 |
| Carta, Q | 1 |
| Pugliese, F | 1 |
| Ball, S | 1 |
| Woods, HF | 1 |
| Mashaly, M | 1 |
| el-Ebrashy, N | 1 |
| Higazi, AM | 1 |
| Einen, MA | 1 |
| Aziz, MT | 1 |
| Leupold, H | 1 |
| Drouin, P | 1 |
| Mejean, L | 1 |
| Rousselle, D | 1 |
| Villaume, C | 1 |
| Derbry, G | 1 |
| Wiegboldt, KA | 1 |
| Orofino, G | 1 |
| Bigotti, A | 1 |
| Brogard, JM | 1 |
| Kuntzmann, F | 1 |
| Touitou, D | 1 |
| Dorner, M | 1 |
| Schatz, H | 1 |
| Edlén, A | 1 |
| Bunnag, SC | 1 |
| Israsena, T | 1 |
| Watananukul, P | 1 |
| Parodi, FA | 1 |
| Mutalik, GS | 1 |
| Mitra, D | 1 |
| Oak, VR | 1 |
| Nayak, NJ | 1 |
| Zöllner, N | 1 |
| Dörfler, H | 1 |
| Wolfram, G | 1 |
| Cheah, JS | 1 |
| Contreras, AR | 1 |
| Gabrielli, S | 1 |
| Baigorria, L | 1 |
| Ser, I | 2 |
| Pedrazzi, F | 1 |
| Bommartini, F | 1 |
| Wadman, B | 1 |
| Werner, I | 1 |
| Gutsche, H | 1 |
| Palmas, S | 1 |
| Onorato, D | 1 |
| Baule, GM | 1 |
| Rojszykowa, E | 1 |
| Henning, H | 1 |
| Look, D | 1 |
| Vernet, A | 1 |
| Zahnd, G | 1 |
| Giraudo, JR | 1 |
| Teale, JD | 1 |
| Love, AH | 1 |
| Carlström, S | 1 |
| Monti, M | 1 |
| Ewald, W | 1 |
| Wicklmayr, M | 1 |
| Nemeth, N | 1 |
| Loubatières, A | 1 |
| Sigroth, K | 1 |
| Steen, B | 1 |
| Svanborg, A | 1 |
| Belser, F | 1 |
| Brögli, H | 1 |
| Constam, G | 1 |
| Zollikofer, H | 1 |
| Persson, I | 2 |
| Madsen, SN | 2 |
| Iunes, M | 1 |
| Mazzarollo, DN | 1 |
| Reis, LC | 1 |
| León Castro, J | 1 |
| Yáñez Polo, MA | 1 |
| Sauret Valet, J | 1 |
| De la Lama, J | 1 |
| Concha, E | 1 |
| Veit, O | 1 |
| Marble, A | 1 |
| Frey, H | 1 |
| Hasslacher, C | 1 |
| Fairman, MJ | 1 |
| Galbraith, HJ | 1 |
| Stratmann, FW | 1 |
| Lozano-Castaneda, O | 2 |
| Garcia Viveros, M | 2 |
| Gomez Peréz, FJ | 1 |
| Rull, JA | 2 |
| Rostlapil, J | 1 |
| Zrůstová, M | 1 |
| Prado, R | 1 |
| Müller, R | 1 |
| Sinha, S | 1 |
| Goldstein, HH | 1 |
| Burns, FH | 1 |
| Steinbeck, AW | 1 |
| Taft, P | 1 |
| Niklas, L | 1 |
| Wiederhold, K | 1 |
| Otto, H | 1 |
| de Pupo, AA | 1 |
| da Rocha, DM | 1 |
| López Sánchez, A | 1 |
| Berral Domínguez, A | 1 |
| Benítez Rivero, A | 1 |
| Montagut Sánchez, M | 1 |
| Ortiz de Saracho, L | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Tolerance and Acceptability of Glibentek in Patients With Neonatale Diabetes Secondary to Mutations in K+-ATP Channels[NCT02375828] | Phase 3 | 10 participants (Actual) | Interventional | 2015-03-20 | Completed | ||
| Impact of Timing of Initiation of Sulphonylurea Therapy on Neurodevelopmental Outcomes in Individuals With Intermediate Developmental Delay, Epilepsy and Neonatal Diabetes (iDEND) Syndrome Due to the V59M Mutation in the KCNJ11 Gene[NCT05751525] | 21 participants (Anticipated) | Observational | 2016-07-01 | Recruiting | |||
| Sulfonylureas in Neonatal Diabetes Mellitus With Mutations of 2 Type of Subunits Kir6.2 and SUR1 of the Pancreatic Beta-cell ATP-sensitive K+ Channel.[NCT00610038] | Phase 2 | 19 participants (Actual) | Interventional | 2006-07-31 | Completed | ||
| Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to ABCC8 (SUR1) Mutations[NCT02624830] | Phase 4 | 30 participants (Anticipated) | Interventional | 2019-02-15 | Recruiting | ||
| A Prospective Study of Sulfonylureas in Patients With Diabetes Due to Kir6.2 Mutations[NCT00334711] | 50 participants | Interventional | 2004-01-31 | Completed | |||
| Long-term Sulfonylurea Response and Glucose Control After Switching From Insulin in Children With Diabetes Due to KCNJ11 (KIR6.2) Mutations[NCT02624817] | Phase 4 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Switching From Insulin to Sulfonylurea in Childhood and Adult Diabetes Due to Variants in the HNF1A, HNF4A, or HNF1B Genes[NCT04239586] | Phase 4 | 30 participants (Anticipated) | Interventional | 2017-04-18 | Enrolling by invitation | ||
| Improving Equitable Acces and Adherence to Secondary Prevention Therapy With a Fixed-Dose Combination Drug[NCT01321255] | Phase 3 | 2,118 participants (Actual) | Interventional | 2012-01-31 | Completed | ||
| Pulsatile GnRH in Anovulatory Infertility[NCT00383656] | Phase 2 | 270 participants (Anticipated) | Interventional | 1989-01-31 | Recruiting | ||
| Metformin Pharmacology in Human Cancers[NCT03477162] | Early Phase 1 | 18 participants (Actual) | Interventional | 2018-05-15 | Terminated (stopped due to Enrollment was closed as efforts had become more challenging, and the lab indicated that they were able to obtain their primary objective with the number that had already been enrolled.) | ||
| Effectiveness of the Treatment With Dapagliflozin and Metformin Compared to Metformin Monotherapy for Weight Loss on Diabetic and Prediabetic Patients With Obesity Class III[NCT03968224] | Phase 2/Phase 3 | 90 participants (Anticipated) | Interventional | 2018-07-07 | Recruiting | ||
| Modulation of Insulin Secretion and Insulin Sensitivity in Bangladeshi Type 2 Diabetic Subjects by an Insulin Sensitizer Pioglitazone and T2DM Association With PPARG Gene Polymorphism.[NCT01589445] | Phase 4 | 77 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| A Randomized Phase 3 Trial of Metformin in Patients Initiating Androgen Deprivation Therapy as Prevention and Intervention of Metabolic Syndrome: The Prime Study[NCT03031821] | Phase 3 | 168 participants (Actual) | Interventional | 2018-07-12 | Terminated (stopped due to Manufacturer discontinued the production of study drugs.) | ||
| QT Interval Abnormalities in Sulfonylurea Treated Type 2 Diabetes: Relationship to Treatment Induced Hypoglycaemia and Glycaemic Variability Determined by Simultaneous Ambulatory Monitoring[NCT02298803] | 30 participants (Actual) | Interventional | 2015-01-31 | Completed | |||
| Financial Incentives and SMS to Improve African American Womens' Glycemic Control: Friends & Relatives Improving the Effectiveness of Networks for Diabetes Support Through Text Messaging (FRIENDS Text)[NCT02384265] | 41 participants (Actual) | Interventional | 2012-06-21 | Completed | |||
| A Randomized, Multi-Center, Pivotal Efficacy and Safety Study Evaluating the EndoBarrier® System for Glycemic Improvement in Patients With Inadequately Controlled Type 2 Diabetes and Obesity[NCT04101669] | 240 participants (Anticipated) | Interventional | 2019-09-09 | Recruiting | |||
| Effect of Metformin Glycinate on Postprandial Lipemia, Glycemic Control and Oxidation Markers in Type 2 Diabetes Patients[NCT02064881] | Phase 2/Phase 3 | 72 participants (Anticipated) | Interventional | 2015-10-31 | Recruiting | ||
| A Pilot Study to Evaluate Eli Lilly's Insulin Dosing Algorithm to Control Glycemia in Insulin-treated Adults With Type 2 Diabetes[NCT05514080] | 10 participants (Actual) | Interventional | 2019-12-06 | Completed | |||
| A 16-wk, Uni-center, Randomized, Double-blind, Parallel, Phase 3b Trial to Evaluate Efficacy of Saxagliptin + Dapagliflozin vs.Dapagliflozin With Regard to EGP in T2DM With Insufficient Glycemic Control on Metformin+/-Sulfonylurea Therapy[NCT02613897] | 56 participants (Actual) | Interventional | 2016-01-31 | Completed | |||
| The TELE-DD Project: a Nurse-led Randomised Controlled Trial on Treatment Adherence in Patients With Type 2 Diabetes and Comorbid Depression[NCT04097483] | 428 participants (Actual) | Interventional | 2017-01-31 | Completed | |||
| Does Glycated Hemoglobin Variability in Type 2 Diabetes Differ Depending on the Diabetes Treatment Threshold Used in the Qatari Population: Implication on Diabetes Complication Risk?[NCT02879409] | 150 participants (Anticipated) | Interventional | 2016-11-30 | Active, not recruiting | |||
| The Effects of Metformin on Vascular Structure and Function in Subjects With the Metabolic Syndrome (MET Trial)[NCT00105066] | Phase 2 | 77 participants (Actual) | Interventional | 2004-01-31 | Completed | ||
| The Assessment of the Effect of Metformin and Its Serum Concentration on the Concentration of Substances Associated With the Production of Nitric Oxide in Patients With Impaired Carbohydrate Metabolism[NCT03398356] | Phase 4 | 47 participants (Actual) | Interventional | 2017-10-20 | Completed | ||
| Efficacy and Safety of Metformin Glycinate Compared to Metformin Hydrochloride on the Progression of Type 2 Diabetes[NCT04943692] | Phase 3 | 500 participants (Anticipated) | Interventional | 2021-08-31 | Suspended (stopped due to Administrative decision of the investigation direction) | ||
| Safety and Efficacy of Metformin Glycinate vs Metformin Hydrochloride on Metabolic Control and Inflammatory Mediators in Type 2 Diabetes Patients[NCT01386671] | Phase 3 | 203 participants (Actual) | Interventional | 2014-06-30 | Completed | ||
| Inhibition of Intestinal Glucose Absorption by the Bioflavonoid Quercetin in the Obese and in Obese Type 2 Diabetics[NCT00065676] | Phase 2 | 24 participants (Actual) | Interventional | 2010-04-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
To determine the concentration of metformin in adipose tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 70 |
To determine the concentration of metformin in plasma. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 450 |
To determine the concentration of metformin in tumor-adjacent normal tissue. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 749 |
To determine the concentration of metformin in whole blood. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/mL (Median) |
|---|---|
| Metformin | 514 |
To determine the intra-tumor concentrations of metformin, with a standard deviation ≤25% of the mean, in patients with solid tumors of thoracic origin administered metformin extended release. (NCT03477162)
Timeframe: Within 7 days from surgery
| Intervention | ng/g (Median) |
|---|---|
| Metformin | 1290 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mmol/l (Mean) | |
|---|---|---|
| Baseline FSG | 3rd Month FSG | |
| Metformin ( 002 Group) | 6.2 | 6.5 |
| Pioglitazone (001 Group) | 6.9 | 5.4 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | μU/ml (Mean) | |
|---|---|---|
| Baseline FSI | 3rd month FSI | |
| Metformin ( 002 Group) | 13.0 | 13.9 |
| Pioglitazone (001 Group) | 16.2 | 12.3 |
Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin. (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |
|---|---|---|
| Baseline HbA1c | 3rd month HbA1c | |
| Metformin ( 002 Group) | 7.8 | 7.0 |
| Pioglitazone (001 Group) | 7.3 | 6.7 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostatic Model Assessment of Beta cell function(HOMA percent B) Analysis 2: Homeostatic Model Assessment of Insulin Sensitivity (Homa percent S)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | percentage (Mean) | |||
|---|---|---|---|---|
| Baseline HOMA percent beta cells function | 3rd month HOMA percent beta cells function | Baseline HOMA percent sensitivity | 3rd month HOMA percent sensitivity | |
| Metformin ( 002 Group) | 109.3 | 116.0 | 76.2 | 67.2 |
| Pioglitazone (001 Group) | 118.9 | 132.3 | 51.1 | 69.3 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1: Homeostasis Model Assessment Insulin Resistance(HOMA IR) Analysis 2: Quantitative Insulin sensitivity Check Index(QUICKI)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | Score on a scale ( SI unit) (Mean) | |||
|---|---|---|---|---|
| Baseline QUICKI | 3rd month QUICKI | Baseline HOMA IR | 3rd month HOMA IR | |
| Metformin ( 002 Group) | 0.57 | 0.54 | 3.7 | 4.3 |
| Pioglitazone (001 Group) | 0.52 | 0.59 | 5.1 | 2.9 |
"Response rate was defined by ≥10% decrease of FSG or/and ≥1% decrease of HbA1c from the baseline values after 3 months treatment.48 responded to pioglitazone and 32 responded to metformin.~Analysis 1:Total Cholesterol(TC) Analysis 2:Triglyceride(TG) Analysis 3:High Density Lipoprotein(HDL) Analysis 4:Low Density Lipoprotein(LDL)" (NCT01589445)
Timeframe: 3 months for each drug
| Intervention | mg/dl (Mean) | |||||||
|---|---|---|---|---|---|---|---|---|
| Baseline TC | 3rd month TC | Baseline TG | 3rd month TG | Baseline HDL | 3rd month HDL | Baseline LDL | 3rd month LDL | |
| Metformin (002 Group) | 193.0 | 177.0 | 166.0 | 175.0 | 34.4 | 34.7 | 125.6 | 112.0 |
| Pioglitazone (001 Group) | 182.0 | 178 | 183 | 195 | 33 | 33.2 | 112.8 | 105.5 |
MAGE, a commonly used index of glucose variability, was calculated using data obtained during continuous glucose monitoring. Analysis of correlation between MAGE and delta QTc was undertaken. Please note delta QTc represents the difference between average QTc length during hypoglycemia and average QTc length during normoglycemia. (NCT02298803)
Timeframe: Nocturnal time period (2300-0700) during the 48 hours of Holter monitoring
| Intervention | Correlation coefficient (Number) |
|---|---|
| Hypoglycemia Group | 0.09 |
The day time period for the study spanned from 7 am in the morning until 11 pm in the evening on two consecutive days. The change in the corrected QT interval during day time hypoglycemia was determined by calculating the difference between the average QTc interval length during periods of hypoglycemia (blood glucose level <3.5 mmol/L) and the average QTc interval length during periods of normoglycemia (blood glucose level >3.5 mmol/L) for the day time period. The average QTc interval was calculated using an individually optimised correction formula. If the result of average QTc (hypoglycemia) - average QTc (normoglycemia) was positive, the participant experienced QTc prolongation during hypoglycemia. If the result of average QTc (hypoglycemia) - average QTc (normoglycemia) was negative, the participant experienced QTc shortening during hypoglycemia. (NCT02298803)
Timeframe: Day time period (0700-2300) during the 48 hours of Holter monitoring
| Intervention | Participants (Count of Participants) | |
|---|---|---|
| Experienced QTc prolongation during hypoglycemia | Experienced QTc shortening during hypoglycemia | |
| Hypoglycemia Group | 2 | 1 |
deltaQTc is the difference in QTc observed during periods of hypoglycemia and periods of normoglycemia (for those participants who experienced nocturnal hypoglycemia) (NCT02298803)
Timeframe: Nocturnal time period (2300-0700) during the 48 hours of Holter monitoring
| Intervention | milliseconds (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participant 1 | Participant 4 | Participant 5 | Participant 10 | Participant 15 | Participant 16 | Participant 19 | Participant 24 | |
| Hypoglycemia Group | 10 | 4 | -2 | -6 | -4 | -1 | -8 | 15 |
The MAGE results (in mmol/L) for the eight participants who experienced nocturnal hypoglycemia are included in the table below. (NCT02298803)
Timeframe: 48 hours of continuous glucose monitoring
| Intervention | mmol/L (Number) | |||||||
|---|---|---|---|---|---|---|---|---|
| Participant 1 | Participant 4 | Participant 5 | Participant 10 | Participant 15 | Participant 16 | Participant 19 | Participant 24 | |
| Hypoglycemia Group | 3.9 | 4.7 | 3.0 | 3.9 | 1.8 | 3.6 | 5.7 | 4.3 |
Change in BMI (body mass index) from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | Kg/m^2 (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.8 |
| DAPA (Dapagliflozin Plus Placebo) | -0.66 |
| PCB (Placebo Plus Placebo) | 0.16 |
Change in body weight from baseline to 16 weeks (NCT02613897)
Timeframe: Baseline to 16 weeks
| Intervention | Kg (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -2.28 |
| DAPA (Dapagliflozin Plus Placebo) | -1.76 |
| PCB (Placebo Plus Placebo) | 0.26 |
A measure of the change in fasting plasma glucagon from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -28.52 |
| DAPA (Dapagliflozin Plus Placebo) | 26.89 |
| PCB (Placebo Plus Placebo) | 6.88 |
Measure of change in Free Fatty Acids from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mEq/L (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -0.06 |
| DAPA (Dapagliflozin Plus Placebo) | -0.01 |
| PCB (Placebo Plus Placebo) | 0.00 |
Change in percentage of glucose oxidation from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -22.07 |
| DAPA (Dapagliflozin Plus Placebo) | -46.54 |
| PCB (Placebo Plus Placebo) | 4.65 |
Change in lipid oxidation percentage from baseline to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage of oxidation (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -11.87 |
| DAPA (Dapagliflozin Plus Placebo) | 22.02 |
| PCB (Placebo Plus Placebo) | -6.69 |
Change in blood glucose level measured over a 3 month period from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | percentage change in blood glucose level (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -1.67 |
| DAPA (Dapagliflozin Plus Placebo) | -1.46 |
| PCB (Placebo Plus Placebo) | 0.44 |
Measure of change in OGTT from study start to 16 weeks (NCT02613897)
Timeframe: Change from baseline to 16 weeks
| Intervention | mg/dl (Mean) |
|---|---|
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | -49.62 |
| DAPA (Dapagliflozin Plus Placebo) | -44.24 |
| PCB (Placebo Plus Placebo) | 20.26 |
All subjects received a Double-Tracer Oral Glucose Tolerance Test (OGTT) with 75g of glucose containing 14C-glucose together with intravenous primed-continuous infusion of 3(3H)-glucose for 240 minutes, at baseline (prior to) and after 16 weeks of therapy. Blood and urine samples were obtained during the OGTT to determine EGP. (NCT02613897)
Timeframe: Baseline and 16 weeks
| Intervention | mg/kg*min (Mean) | |
|---|---|---|
| Baseline Measurement | 16 weeks | |
| DAPA (Dapagliflozin Plus Placebo) | 2.56 | 2.8 |
| DAPA/SAXA (Dapagliflozin Plus Saxagliptin) | 2.45 | 2.4 |
| PCB (Placebo Plus Placebo) | 1.95 | 2.15 |
(NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | meters / second (Mean) |
|---|---|
| Placebo | -7.2 |
| Metformin | -7.3 |
to evaluate improvement in endothelial function (NCT00105066)
Timeframe: Baseline and 4.5 months
| Intervention | percentage change in diameter (Mean) |
|---|---|
| Placebo | 8.8 |
| Metformin | 10.5 |
Homeostatic Model Assessment of insulin sensitivity (NCT00105066)
Timeframe: 4.5 months
| Intervention | HOMA Score (Mean) |
|---|---|
| Placebo | 57.4 |
| Metformin | 64.5 |
ADMA- asymmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: before study start; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.51 | 0.52 | 0.50 |
| Group B | 0.57 | 0.55 | 0.52 |
arginine serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 112.18 | 107.72 | 104.72 |
| Group B | 111.72 | 97.69 | 103.76 |
serum concentration of the citrulline (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 21.73 | 25.95 | 26.93 |
| Group B | 28.08 | 27.01 | 29.77 |
DMA- dimethylamine, serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 1.71 | 1.63 | 1.62 |
| Group B | 2.07 | 1.89 | 1.84 |
the serum concentration of the studied drug-metformin (NCT03398356)
Timeframe: 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 4.36 | 5.09 | 4.66 |
| Group B | 4.25 | 7.42 | 4.01 |
SDMA-symmetric dimethylarginine-serum concentration (NCT03398356)
Timeframe: Baseline; 6 weeks from treatment start; 12 weeks from treatment start; 15 weeks from treatment start
| Intervention | µM (Mean) | ||
|---|---|---|---|
| 6 weeks from the start of treatment | 12 weeks from the start of treatment | 15 weeks from the start of treatment | |
| Group A | 0.40 | 0.41 | 0.39 |
| Group B | 0.45 | 0.42 | 0.39 |
26 reviews available for glyburide and Diabetes Mellitus
| Article | Year |
|---|---|
Sulfonylurea for improving neurological features in neonatal diabetes: A systematic review and meta-analyses.
Topics: Adult; Child; Diabetes Mellitus; Epilepsy; Glyburide; Humans; Infant, Newborn; Infant, Newborn, Dise | 2022 |
Availability and affordability of essential medicines and diagnostic tests for diabetes mellitus in Africa.
Topics: Costs and Cost Analysis; Diabetes Mellitus; Diagnostic Tests, Routine; Drugs, Essential; Glyburide; | 2022 |
Glibenclamide as a neuroprotective antidementia drug.
Topics: Alzheimer Disease; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Neuroprotective Agents | 2022 |
Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dose-Response Rela | 2019 |
Review: Glycation of human serum albumin.
Topics: Biomarkers; Blood Glucose; Diabetes Mellitus; Fatty Acids; Glyburide; Glycated Serum Albumin; Glycat | 2013 |
Successful transition from insulin to sulfonylurea therapy in a patient with monogenic neonatal diabetes owing to a KCNJ11 F333L [corrected] mutation.
Topics: Blood Glucose; Diabetes Mellitus; DNA Mutational Analysis; Follow-Up Studies; Glyburide; Humans; Hyp | 2013 |
[Progress in therapy for diabetes mellitus--insulin-secretion inducing oral hypoglycemic agents].
Topics: Administration, Oral; Cyclohexanes; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infan | 2009 |
[Antidiabetic therapy in diabetic patients with coronary heart disease].
Topics: Administration, Oral; Coronary Disease; Delayed-Action Preparations; Diabetes Complications; Diabete | 2003 |
[Modern oral sugar-reducing drugs: focus to glibenclamide].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Trea | 2007 |
Insulin resistance in noninsulin-dependent diabetes mellitus: impact of sulfonylurea agents in vivo and in vitro.
Topics: Diabetes Mellitus; Glucose; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Resistance; Rec | 1983 |
[25 years of diabetic treatment by oral hypoglycemic agents: successes and failures].
Topics: Aged; Aging; Blood Glucose; Cardiovascular Diseases; Chlorpropamide; Diabetes Complications; Diabete | 1984 |
[Effects and limitations of treatment of diabetes. On insulin secretory capacity (author's transl)].
Topics: C-Peptide; Diabetes Mellitus; Glyburide; Humans; Insulin; Insulin Secretion | 1980 |
[Behavior of lactate and pyruvate in diabetics during ambulatory treatment with biguanides or with a combination of biguanides and sulfonylureas. II].
Topics: Aged; Ambulatory Care; Biguanides; Diabetes Mellitus; Diabetic Ketoacidosis; Drug Combinations; Fema | 1980 |
Sulfonylureas and platelet function.
Topics: Adenosine Diphosphate; Blood Glucose; Blood Platelets; Collagen; Diabetes Mellitus; Diabetic Angiopa | 1981 |
Protein phosphorylation and beta-cell function.
Topics: Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Awards and Prizes; Brain; Calciu | 1994 |
The management of diabetes in patients with advanced cancer.
Topics: Blood Glucose; Carcinoma, Squamous Cell; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitu | 1997 |
Anti-diabetic drugs as a cause of hypoglycaemia among acute medical admissions in Hong Kong and Singapore--relationship to the prescribing patterns in diabetic patients.
Topics: Acute Disease; Age Factors; Aged; China; Diabetes Mellitus; Drug Prescriptions; Drug Utilization; Gl | 1998 |
Drug therapy of postprandial hyperglycaemia.
Topics: 1-Deoxynojirimycin; Acarbose; Amyloid; Carbamates; Diabetes Mellitus; Enzyme Inhibitors; Glucosamine | 1999 |
[Should the occurrence of a first coronary event change the management of diabetes?].
Topics: Acidosis, Lactic; Acute Disease; Adrenergic beta-Antagonists; Blood Glucose; Cardiovascular Agents; | 2000 |
[New aspects of therapy with oral antidiabetic agents].
Topics: Acidosis; Biguanides; Blood Proteins; Chlorpropamide; Diabetes Mellitus; Diabetic Nephropathies; Dru | 1979 |
[Glipizide a new oral antidiabetic agent (comprehensive review)].
Topics: Animals; Blood Glucose; Chemical Phenomena; Chemistry; Diabetes Mellitus; Dogs; Drug Evaluation; Gli | 1976 |
[What is achieved by the therapy with oral antidiabetics?].
Topics: Administration, Oral; Adult; Biguanides; Chlorpropamide; Diabetes Mellitus; Diabetic Angiopathies; D | 1976 |
Oral treatment in diabetes.
Topics: Acetohexamide; Acidosis; Administration, Oral; Animals; Biguanides; Cardiovascular Diseases; Chlorpr | 1972 |
[Central role of the pancreas in the mechanism of action of hypoglycemic sulfonamides and their consequences in the therapy and prevention of diabetes].
Topics: Animals; Diabetes Mellitus; Glyburide; Growth; Growth Hormone; Humans; Hypoglycemic Agents; Pancreas | 1970 |
Glibenclamide, a new sulphonylurea: whither oral hypoglycaemic agents?
Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Carbohydrates; Child; Coronary Disease; Diab | 1971 |
Glibenclamide: a review.
Topics: Administration, Oral; Adolescent; Adult; Aged; Animals; Biguanides; Blood Glucose; Carbon Isotopes; | 1971 |
60 trials available for glyburide and Diabetes Mellitus
| Article | Year |
|---|---|
Glibenclamide oral suspension: Suitable and effective in patients with neonatal diabetes.
Topics: Administration, Oral; Adolescent; Blood Glucose; Child; Child, Preschool; Diabetes Mellitus; Female; | 2019 |
Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations.
Topics: Administration, Oral; Adolescent; Brain; Child; Child, Preschool; Diabetes Mellitus; Drug Substituti | 2015 |
Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations.
Topics: Administration, Oral; Adolescent; Brain; Child; Child, Preschool; Diabetes Mellitus; Drug Substituti | 2015 |
Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations.
Topics: Administration, Oral; Adolescent; Brain; Child; Child, Preschool; Diabetes Mellitus; Drug Substituti | 2015 |
Sulfonylurea Therapy Benefits Neurological and Psychomotor Functions in Patients With Neonatal Diabetes Owing to Potassium Channel Mutations.
Topics: Administration, Oral; Adolescent; Brain; Child; Child, Preschool; Diabetes Mellitus; Drug Substituti | 2015 |
Modulation of circulating and adipose tissue adiponectin levels by antidiabetic therapy.
Topics: Adipocytes; Adiponectin; Adipose Tissue; Adult; Aged; Biopsy; Chromans; Culture Media, Conditioned; | 2003 |
The effects of KATP channel modulators on counterregulatory responses and cognitive function during acute controlled hypoglycaemia in healthy men: a pilot study.
Topics: Adenosine Triphosphate; Adult; Blood Glucose; Cognition; Diabetes Mellitus; Diazoxide; Glucose Clamp | 2003 |
Effects of sulfonylurea hypoglycemic agents and adenosine triphosphate dependent potassium channel antagonists on ventricular arrhythmias in patients with decompensated heart failure.
Topics: Aged; Analysis of Variance; Anti-Arrhythmia Agents; Chi-Square Distribution; Diabetes Complications; | 2003 |
Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus.
Topics: Adult; Aged; Arginine; Biomarkers; Blood Glucose; Blood Pressure; Brachial Artery; C-Reactive Protei | 2007 |
[Modification of glucose resorption by bulk materials].
Topics: Alginates; Cellulose; Diabetes Mellitus; Dietary Fiber; Food Additives; Galactans; Glucose; Glucose | 1980 |
[Interaction of sulfinpyrazone (Anturan) and glibenclamide (Euglucon) in type II diabetic patients].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Interactions; Female; Glyburide; Huma | 1983 |
[Glibenclamide in type II diabetes as compared with placebo].
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Glyburide; Humans; Ketone | 1983 |
Glyburide (DiaBeta): a new second-generation hypoglycemic agent.
Topics: Animals; Biological Availability; Blood Coagulation; Cardiovascular System; Clinical Trials as Topic | 1984 |
Effect of sulphonylurea on insulin secretion and glucose control in insulin-treated diabetics.
Topics: Adult; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Glyburide; H | 1981 |
Glibenclamide and gliquidone in the treatment of non-insulin-dependent diabetes mellitus.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Glyburide; Glycated Hemogl | 1982 |
Effect of treatment of the concentration of lipoproteins and the postheparin-lipolytic activity in the plasma of noninsulin-dependent diabetics.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Female; Glyburide; Heparin; Humans; Insulin, Long-Acting; Li | 1982 |
[Carbohydrate metabolism in bezafibrate therapy. Controlled study of glibenclamide-treated diabetics with hyperlipidemia].
Topics: Aged; Bezafibrate; Carbohydrate Metabolism; Clinical Trials as Topic; Clofibrate; Clofibric Acid; Di | 1982 |
[Glibenclamide-insulin combination in the management of secondary failure of sulfonyl-urea medication].
Topics: Aged; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; Glyburide; Humans; Insulin; | 1982 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
Efficacy of metformin in patients with non-insulin-dependent diabetes mellitus. The Multicenter Metformin Study Group.
Topics: Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Double-Blind | 1995 |
United Kingdom Prospective Diabetes Study (UKPDS). 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin, or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years.
Topics: Adult; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type | 1995 |
Metabolic effects of omega-3 fatty acids in type 2 (non-insulin-dependent) diabetic patients.
Topics: Adult; Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Dietary Fats, Unsatur | 1993 |
Sulfonylurea treatment prevents recurrence of hyperglycemia in obese African-American patients with a history of hyperglycemic crises.
Topics: Adult; Black or African American; Black People; Blood Glucose; C-Peptide; Combined Modality Therapy; | 1997 |
Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function.
Topics: Adult; Aged; Diabetes Complications; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agen | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
Topics: Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Glyburi | 1998 |
Glucose disturbances and regulation with glibenclamide in thalassemia.
Topics: Adolescent; Adult; beta-Thalassemia; Blood Glucose; Child; Diabetes Mellitus; Diet; Exercise; Glucos | 1998 |
Evaluation of oxidative stress before and after control of glycemia and after vitamin E supplementation in diabetic patients.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Femal | 2000 |
[The effect of metipranolol on the carbohydrate metabolism in diabetics treated with glibenclamide (author's transl)].
Topics: Adult; Aged; Blood Glucose; Carbohydrate Metabolism; Clinical Trials as Topic; Diabetes Mellitus; Do | 1979 |
Letter: Fibrinolytic activity in treatment of diabetes.
Topics: Diabetes Mellitus; Female; Fibrinolysis; Glyburide; Humans; Male; Phenformin | 1976 |
[Clinico-pharmacological study of a new oral hypoglycemic agent].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Glyburide; Humans | 1978 |
[Treatment with oral hypoglycemia agents in diabetes mellitus. Controlled clinical study of 2 combinations of glibenclamide and phenformin. II].
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Drug Combinations; | 1978 |
[Therapy of diabetes with oral hypoglycemic agents. Controlled clinical study of 2 glibenclamide-phenformin combinations. I].
Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Drug Therapy, Combination; F | 1978 |
[Comparison of glibenclamide, gliquidone, glisoxepide and placebo in maturity onset diabetics of differing degrees of severity (author's transl)].
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Evaluation Studies as Topic; Glyburide; Humans; Placebo | 1979 |
Glibenclamide and glipizide in maturity onset diabetes. A double-blind cross-over study.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Double-Blind Method; Female; Glipi | 1979 |
Effects of the sulphonylurea drugs gliclazide and glibenclamide on blood glucose control and platelet function.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Gliclazide; Glyburide; Humans; Male; Middle A | 1979 |
Clinical comparison between glibornuride (Glutril) and glibenclamide in maturity-onset diabetes: a controlled double-blind trial.
Topics: Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Dose-Response Relationship, Drug; | 1976 |
[Clinical comparison between glibornuride (Glutril) and glibenclamide in senile diabetes. A controlled double-blind trial].
Topics: Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Female; Glyburide; | 1976 |
Clinical comparison between glipentide (Staticum) and glibenclamide in diabetics.
Topics: Adolescent; Adult; Aged; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Female; Glucose | 1977 |
Clinical studies of the interaction between tolmetin and glibenclamide.
Topics: Adult; Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Drug Interactions; Female; Gl | 1977 |
[The diuretic action of a new antidiabetic drug (glybenclamide)].
Topics: Clinical Trials as Topic; Diabetes Insipidus; Diabetes Mellitus; Diuresis; Diuretics; Glomerular Fil | 1975 |
[Increase of the betazytotropic effect of intravenous arginine administration through glibenclamide in subjects with healthy metabolism and in patients with latent and manifest diabetes].
Topics: Adult; Aged; Arginine; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Drug Syne | 1975 |
[Our observations on diabetics treated with glibenclamide].
Topics: Biguanides; Clinical Trials as Topic; Diabetes Mellitus; Drug Evaluation; Drug Therapy, Combination; | 1976 |
[Therapeutic effect of glibenclamide contrasted with other oral antidiabetic agents].
Topics: Administration, Oral; Adult; Biguanides; Chlorpropamide; Chronic Disease; Clinical Trials as Topic; | 1975 |
[Glibenclamide-phenformin combination in the treatment of diabetes in adults].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Combinations; Drug Evaluation; Female | 1975 |
Comparison of combined therapies in treatment of secondary failure to glyburide.
Topics: Blood Glucose; Body Weight; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Administra | 1992 |
[Evaluation of the efficacy of metformin-glibenclamide treatment in overweight non-insulin dependent diabetics].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glybu | 1992 |
Combined therapy for obese type 2 diabetes: suppertime mixed insulin with daytime sulfonylurea.
Topics: Adult; Blood Glucose; C-Peptide; Cholesterol; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Adm | 1992 |
U.K. prospective diabetes study. II. Reduction in HbA1c with basal insulin supplement, sulfonylurea, or biguanide therapy in maturity-onset diabetes. A multicenter study.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Female; Gl | 1985 |
Combination of two sulfonylureas. Does it make sense.
Topics: Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, | 1988 |
[The influence of various sulphonylurea derivatives on the oral glucose-tolerance tests in healthy subjects and obese and maturity-onset diabetics (author's transl)].
Topics: Administration, Oral; Adult; Blood Glucose; Diabetes Mellitus; Glucose; Glucose Tolerance Test; Glyb | 1974 |
Dose-response relationships of tolbutamide and glibenclamide in diabetes mellitus.
Topics: Adult; Aged; Blood Glucose; Clinical Trials as Topic; Colorimetry; Diabetes Mellitus; Dose-Response | 1974 |
[Blood sugar, serum insulin, nonesterified fatty acids and somatotropin in daily profile in adult diabetics under monotherapy with various sulfonylureas].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Diet, Diabetic; Fatty Acids, Nonesterified; Glyburide | 1974 |
[Initial results in the treatment of diabetes mellitus with an association of glibenclamide and phenformin].
Topics: Adult; Aged; Blood Glucose; Body Weight; Cholesterol; Clinical Trials as Topic; Diabetes Mellitus; D | 1974 |
[Controlled clinical study of a new oral antidiabetic formed by a glibenclamide-phenformin association].
Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Combinations; Drug Evaluation; Female; Glybu | 1974 |
Controlled extension of oral antidiabetic therapy on former insulin dependent diabetics by means of the combined i.v. glibenclamide-glucose-response-test.
Topics: Administration, Oral; Adult; Age Factors; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Co | 1972 |
[Clinical testing of a sulphonylurea derivative, glibornuride].
Topics: Adult; Aged; Biguanides; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Diet Therapy; F | 1972 |
A clinical evaluation of glibenclamide (HB 419, "Daonil") a new antidiabetic sulphonylurea.
Topics: Administration, Oral; Adolescent; Adult; Aged; Alcohol Drinking; Clinical Trials as Topic; Diabetes | 1972 |
Oral substitutes for insulin: modern appraisal of their action and indications.
Topics: Adolescent; Adult; Aged; Animals; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diet, | 1972 |
[Clinical experimentation with a new oral antidiabetic].
Topics: Adult; Aged; Clinical Trials as Topic; Diabetes Mellitus; Drug Combinations; Evaluation Studies as T | 1972 |
[Clinical study of a new sulfonylurea antidiabetic, glibornuride].
Topics: Aged; Clinical Trials as Topic; Diabetes Mellitus; Evaluation Studies as Topic; Female; Glyburide; H | 1972 |
[Therapy of diabetes in adults using Glibornurid. Results and clinical studies].
Topics: Aged; Blood Glucose; Body Weight; Camphanes; Clinical Trials as Topic; Diabetes Mellitus; Drug Hyper | 1973 |
[Clinical testing of a sulfonylurea preparation (glibenclamide)].
Topics: Adult; Aged; Chlorpropamide; Clinical Trials as Topic; Diabetes Mellitus; Diet Therapy; Female; Glyb | 1969 |
[Prolonged treatment with glibenclamide in various types of diabetic patient].
Topics: Clinical Trials as Topic; Diabetes Mellitus; Female; Glyburide; Humans; Male; Sulfonylurea Compounds | 1971 |
The clinical evaluation of an oral antidiabetic drug.
Topics: Administration, Oral; Blood Glucose; Clinical Trials as Topic; Diabetes Mellitus; Glyburide; Humans; | 1971 |
330 other studies available for glyburide and Diabetes Mellitus
| Article | Year |
|---|---|
Dual action spirobicycloimidazolidine-2,4-diones: antidiabetic agents and inhibitors of aldose reductase-an enzyme involved in diabetic complications.
Topics: Aldehyde Reductase; Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Diabetes Mell | 2013 |
Blood pressure and blood sugar-lowering effects of purified gambir on diabetic hypertensive Wistar Kyoto rats.
Topics: Alloxan; Animals; Antioxidants; Blood Glucose; Blood Pressure; Captopril; Catechin; Diabetes Mellitu | 2022 |
Early Postnatal Use of Glibenclamide in Permanent Neonatal Diabetes Secondary to Antenatally Diagnosed KJCN11 Mutation.
Topics: Blood Glucose; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Infant, Ne | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Neonatal diabetes with a rare LRBA mutation.
Topics: Adaptor Proteins, Signal Transducing; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; I | 2022 |
Case report: Better late than never, but sooner is better: switch from CSII to sulfonylureas in two patients with neonatal diabetes due to KCNJ11 variants.
Topics: Blood Glucose; Blood Glucose Self-Monitoring; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Age | 2023 |
Use of Antidiabetic drugs during pregnancy among U.S. women with Livebirth deliveries in the Mini-Sentinel system.
Topics: Administrative Claims, Healthcare; Adolescent; Adult; Child; Databases, Factual; Diabetes Mellitus; | 2019 |
Diabetes treatment in two pregnant women with permanent neonatal diabetes mellitus due to a KCNJ11 mutation.
Topics: Adult; Diabetes Mellitus; Drug Therapy, Combination; Female; Fetal Macrosomia; Glyburide; Glycemic C | 2020 |
Glyburide inhibits non-enzymatic glycation of HSA: An approach for the management of AGEs associated diabetic complications.
Topics: Diabetes Complications; Diabetes Mellitus; Glucose; Glyburide; Glycation End Products, Advanced; Gly | 2021 |
Case report: coeliac disease as a cause of secondary failure of glibenclamide therapy in a patient with permanent neonatal diabetes due to KCNJ11/R201C mutation.
Topics: Amino Acid Substitution; Arginine; Celiac Disease; Child, Preschool; Combined Modality Therapy; Cyst | 2021 |
Personalized precision medicine in extreme preterm infants with transient neonatal diabetes mellitus.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Genetic Testing; Glyburide; High-Throughput Nucleot | 2017 |
Hypoglycemic and Antihyperglycemic Activities of Nine Medicinal Herbs Used as Antidiabetic in the Region of Lubumbashi (DR Congo).
Topics: Animals; Asteraceae; Blood Glucose; Cassia; Democratic Republic of the Congo; Diabetes Mellitus; Glu | 2017 |
Early transition from insulin to sulfonylureas in neonatal diabetes and follow-up: Experience from China.
Topics: China; Chromosome Deletion; Chromosome Disorders; Chromosomes, Human, Pair 1; Cohort Studies; Diabet | 2018 |
Primary sulphonylurea therapy in a newborn with transient neonatal diabetes attributable to a paternal uniparental disomy 6q24 (UPD6).
Topics: Administration, Oral; Berlin; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Dr | 2018 |
Methods for Characterizing Disease-Associated ATP-Sensitive Potassium Channel Mutations.
Topics: Animals; Blotting, Western; Chlorocebus aethiops; Congenital Hyperinsulinism; COS Cells; Diabetes Me | 2018 |
Emergence of insulin resistance following empirical glibenclamide therapy: a case report of neonatal diabetes with a recessive INS gene mutation.
Topics: Blood Glucose; Consanguinity; Diabetes Mellitus; Glyburide; Homozygote; Humans; Infant, Newborn; Inf | 2018 |
Risk of Hypoglycemia Following Hospital Discharge in Patients With Diabetes and Acute Kidney Injury.
Topics: Acute Kidney Injury; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetic Nephropathies; Female; | 2018 |
To diet or not to diet in neonatal diabetes responding to sulfonylurea treatment.
Topics: Combined Modality Therapy; Diabetes Mellitus; Diet, Carbohydrate-Restricted; Female; Glyburide; Huma | 2018 |
Contribution of systemic inflammation to permanence of K
Topics: Animals; Blood Glucose; Cytokines; Diabetes Mellitus; Glucagon; Glucagon-Like Peptide 1; Glyburide; | 2018 |
The relationship between illnesses and medical drug consumption with the occurrence of traffic accidents among truck and bus drivers in Tehran, Iran.
Topics: Accidents, Traffic; Adult; Automobile Driving; Cross-Sectional Studies; Diabetes Mellitus; Drug Util | 2019 |
Switching to sulphonylureas in children with iDEND syndrome caused by KCNJ11 mutations results in improved cerebellar perfusion.
Topics: Adolescent; Cerebellum; Child; Child, Preschool; Diabetes Mellitus; Female; Glyburide; Humans; Infan | 2013 |
KCNJ11 in-frame 15-bp deletion leading to glibenclamide- responsive neonatal diabetes mellitus in a Chinese child.
Topics: Asian People; Diabetes Mellitus; DNA Mutational Analysis; Female; Gene Deletion; Glyburide; Humans; | 2013 |
Glibenclamide for neonatal diabetes.
Topics: Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Potassium Channels, Inwar | 2013 |
Low glibenclamide concentrations affect endoplasmic reticulum stress in INS-1 cells under glucotoxic or glucolipotoxic conditions.
Topics: Animals; Apoptosis; Biomarkers; Cell Line, Tumor; Cell Survival; Diabetes Mellitus; Endoplasmic Reti | 2013 |
Permanent neonatal diabetes mellitus in monozygotic twins achieving low-dose sulfonylurea therapy.
Topics: Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Glyburide; Humans; Hypoglycemic Agents; | 2014 |
Antihyperglycemic activities of leaves of three edible fruit plants (Averrhoa carambola, Ficus hispida and Syzygium samarangense) of Bangladesh.
Topics: Animals; Bangladesh; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Ficus; Frui | 2012 |
Antihyperglycemic and antinociceptive activity evaluation of 'khoyer' prepared from boiling the wood of Acacia catechu in water.
Topics: Acacia; Acetic Acid; Analgesics; Animals; Aspirin; Bangladesh; Behavior, Animal; Blood Glucose; Diab | 2013 |
KCNJ11 in-frame 15-bp deletion leading to glibenclamide-responsive neonatal diabetes mellitus in a Chinese child.
Topics: Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Mutation; Potass | 2013 |
A case report on escitalopram-induced hyperglycaemia in a diabetic patient.
Topics: Aged, 80 and over; Antidepressive Agents; Citalopram; Depression; Diabetes Mellitus; Drug Therapy, C | 2013 |
Long-term efficacy of glibenclamide and sitagliptin therapy in adult patients with KCNJ11 permanent diabetes.
Topics: Adolescent; Adult; Diabetes Mellitus; DNA; DNA Mutational Analysis; Female; Follow-Up Studies; Gluca | 2014 |
Permanent neonatal diabetes mellitus due to an ABCC8 mutation: a case report.
Topics: Blood Glucose; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; M | 2014 |
Patient with iDEND syndrome-related mutation.
Topics: Diabetes Mellitus; Epilepsy; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Infant | 2014 |
Coadministration of co-trimoxazole with sulfonylureas: hypoglycemia events and pattern of use.
Topics: Aged; Aged, 80 and over; Anti-Infective Agents; Cohort Studies; Diabetes Mellitus; Drug Interactions | 2015 |
Glycemic control and motor development in a patient with intermediate DEND.
Topics: Child Development; Diabetes Mellitus; Epilepsy; Glucose; Glyburide; Humans; Infant; Infant, Newborn, | 2014 |
No sign of proliferative retinopathy in 15 patients with permanent neonatal diabetes with a median diabetes duration of 24 years.
Topics: Adolescent; Adult; Diabetes Mellitus; Diabetic Retinopathy; Female; Follow-Up Studies; Glyburide; Hu | 2014 |
Fetal macrosomia and neonatal hyperinsulinemic hypoglycemia associated with transplacental transfer of sulfonylurea in a mother with KCNJ11-related neonatal diabetes.
Topics: Adult; Congenital Hyperinsulinism; Diabetes Mellitus; Female; Fetal Macrosomia; Glyburide; Humans; H | 2014 |
Trends in prevalence, incidence and pharmacologic management of diabetes mellitus among seniors newly admitted to long-term care facilities in Saskatchewan between 2003 and 2011.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glyburide; Homes for the Aged; Humans; Hypoglyce | 2015 |
Remission of severe neonatal diabetes with very early sulfonylurea treatment.
Topics: Child; Diabetes Mellitus; Drug Administration Schedule; Early Medical Intervention; Female; Glyburid | 2015 |
Estimating kidney function and use of oral antidiabetic drugs in elderly.
Topics: Administration, Oral; Age Factors; Aged; Aged, 80 and over; Biomarkers; Creatinine; Cross-Sectional | 2015 |
Age at the time of sulfonylurea initiation influences treatment outcomes in KCNJ11-related neonatal diabetes.
Topics: Adolescent; Adult; Age Factors; Age of Onset; Child; Child, Preschool; Diabetes Mellitus; Dose-Respo | 2015 |
Changing Patterns of Glucose-Lowering Medication Use in VA Nursing Home Residents With Diabetes, 2005 to 2011.
Topics: Aged; Aged, 80 and over; Cohort Studies; Diabetes Mellitus; Drug Utilization; Female; Glyburide; Hum | 2015 |
Permanent neonatal diabetes by a new mutation in KCNJ11: unsuccessful switch to sulfonylurea.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Drug Substitution; Glyburide; Humans; Hypoglycemic Agen | 2015 |
Successful treatment of young infants presenting neonatal diabetes mellitus with continuous subcutaneous insulin infusion before genetic diagnosis.
Topics: Blood Glucose; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 1; Female; Glyburide; Humans; H | 2016 |
Permanent neonatal diabetes mellitus - a case report of a rare cause of diabetes mellitus in East Africa.
Topics: Administration, Oral; Child, Preschool; Diabetes Mellitus; Diabetic Ketoacidosis; Glyburide; Humans; | 2015 |
Molecular and clinical features of K
Topics: Amino Acid Substitution; Congenital Hyperinsulinism; Diabetes Mellitus; DNA Mutational Analysis; Dru | 2017 |
Glibenclamide impairs responses of neutrophils against Burkholderia pseudomallei by reduction of intracellular glutathione.
Topics: Acetylcysteine; Adult; Burkholderia pseudomallei; Case-Control Studies; Cell Movement; Cytokines; Di | 2016 |
First case of neonatal diabetes with KCNJ11 Q52R mutation successfully switched from insulin to sulphonylurea treatment.
Topics: Developmental Disabilities; Diabetes Mellitus; Epilepsy; Glyburide; Humans; Hypoglycemic Agents; Inf | 2017 |
[Effects of different sulfonylureas on the warm-up phenomenon in diabetes patients with coronary artery disease].
Topics: Angina Pectoris; Coronary Angiography; Coronary Artery Disease; Diabetes Complications; Diabetes Mel | 2017 |
Implementation and Assessment of an Ambulatory Prescribing Guidance Tool to Improve Patient Safety in the Geriatric Population.
Topics: Aged; Ambulatory Care; Decision Support Systems, Clinical; Diabetes Mellitus; Drug Interactions; Gly | 2017 |
Permanent neonatal diabetes mellitus caused by a novel homozygous (T168A) glucokinase (GCK) mutation: initial response to oral sulphonylurea therapy.
Topics: Administration, Oral; Diabetes Mellitus; Family Health; Glucokinase; Glyburide; Homozygote; Humans; | 2008 |
SUR receptor activity vs. incidence of hypoglycaemia and cardiovascular mortality with sulphonylurea therapy for diabetics.
Topics: ATP-Binding Cassette Transporters; Diabetes Mellitus; Glyburide; Humans; Hypoglycemia; Potassium Cha | 2008 |
Oral glyburide, but not glimepiride, blocks the infarct-size limiting effects of pioglitazone.
Topics: Administration, Oral; Animals; Body Weight; Coronary Vessels; Data Interpretation, Statistical; Deca | 2008 |
Familial permanent neonatal diabetes with KCNJ11 mutation and the response to glyburide therapy--a three-year follow-up.
Topics: Blood Glucose; Child, Preschool; Diabetes Mellitus; Female; Follow-Up Studies; Glyburide; Glycated H | 2008 |
Glibenclamide unresponsiveness in a Brazilian child with permanent neonatal diabetes mellitus and DEND syndrome due to a C166Y mutation in KCNJ11 (Kir6.2) gene.
Topics: Brazil; Child, Preschool; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Female; Glyburide | 2008 |
Sulfonylurea treatment in a girl with neonatal diabetes (KCNJ11 R201H) and celiac disease: impact of low compliance to the gluten free diet.
Topics: Amino Acid Substitution; Autoantibodies; Diabetes Mellitus; Diet, Gluten-Free; Female; Glyburide; Gl | 2009 |
Tooth discoloration in patients with neonatal diabetes after transfer onto glibenclamide: a previously unreported side effect.
Topics: Dental Enamel Hypoplasia; Diabetes Mellitus; Glyburide; Humans; Infant, Newborn; Insulin; Mutation; | 2009 |
An oral sulfonylurea in the treatment of transient neonatal diabetes mellitus.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Glyburide; | 2009 |
Glibenclamide treatment in relapsed transient neonatal diabetes as a result of a KCNJ11 activating mutation (N48D).
Topics: Child; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant; Male; Recurrence | 2009 |
Successful sulfonylurea treatment of an insulin-naïve neonate with diabetes mellitus due to a KCNJ11 mutation.
Topics: Blood Glucose; Child; Diabetes Mellitus; Early Diagnosis; Female; Glyburide; Humans; Hypoglycemic Ag | 2010 |
Hypoglycemic effects of Cecropia pachystachya in normal and alloxan-induced diabetic rats.
Topics: Alloxan; Animals; Antioxidants; Ascorbic Acid; Blood Glucose; Cecropia Plant; Diabetes Mellitus; Dia | 2010 |
Antidiabetic effect of Ficus religiosa extract in streptozotocin-induced diabetic rats.
Topics: Administration, Oral; Animals; Body Weight; Cholesterol; Diabetes Mellitus; Ficus; Glyburide; Glycog | 2010 |
Exploring the mechanism of endothelial involvement in acidosis-induced vasodilatation of aortic tissues from normal and diabetic rats.
Topics: 4-Aminopyridine; Acidosis; Animals; Aorta; Barium Compounds; Chlorides; Diabetes Mellitus; Endotheli | 2010 |
Glyburide increases risk in patients with diabetes mellitus after emergent percutaneous intervention for myocardial infarction--a nationwide study.
Topics: Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Denmark; Diabetes Mellitus; Female; Glyburi | 2011 |
Diabetes mellitus in older adults: time for an overtreatment quality indicator.
Topics: Aged, 80 and over; Diabetes Mellitus; Drug Overdose; Female; Glyburide; Humans; Hypoglycemia; Hypogl | 2010 |
Successful sulfonylurea treatment of a neonate with neonatal diabetes mellitus due to a new KCNJ11 mutation.
Topics: Diabetes Mellitus; Female; Glyburide; Heterozygote; Humans; Hypoglycemic Agents; Infant, Newborn; Mu | 2011 |
Impact of renal impairment on the risk of severe hypoglycaemia associated with the use of insulin and glyburide.
Topics: Diabetes Mellitus; Glomerular Filtration Rate; Glyburide; Humans; Hypoglycemia; Hypoglycemic Agents; | 2011 |
Acute sulfonylurea therapy at disease onset can cause permanent remission of KATP-induced diabetes.
Topics: Animals; Blood Glucose; Diabetes Mellitus; Glucose; Glyburide; Humans; Hypoglycemic Agents; Insulin | 2011 |
No beta cell desensitisation after a median of 68 months on glibenclamide therapy in patients with KCNJ11-associated permanent neonatal diabetes.
Topics: Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Mutation; Potassium Chan | 2011 |
Comparable long-term mortality risk associated with individual sulfonylureas in diabetes patients with heart failure.
Topics: Aged; Aged, 80 and over; Diabetes Mellitus; Female; Glipizide; Glyburide; Heart Failure; Humans; Hyp | 2011 |
Glycemic control and hypoglycemia in Veterans Health Administration patients converted from glyburide to glipizide.
Topics: Aged; Blood Glucose; Creatinine; Diabetes Mellitus; Female; Glipizide; Glyburide; Glycated Hemoglobi | 2011 |
Personalized medicine switching from insulin to sulfonylurea in permanent neonatal diabetes mellitus dictated by a novel activating ABCC8 mutation.
Topics: Adult; ATP-Binding Cassette Transporters; Diabetes Mellitus; Drug Substitution; Female; Glyburide; H | 2012 |
Transient neonatal diabetes with two novel mutations in the KCNJ11 gene and response to sulfonylurea treatment in a preterm infant.
Topics: Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant; Infant, Newborn; Infant, Newborn, | 2011 |
Diabetes caused by Kir6.2 mutation: successful treatment with oral glibenclamide switched from continuous subcutaneous insulin infusion in the early phase of the disease.
Topics: Administration, Oral; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; In | 2012 |
Prescription patterns for diabetes mellitus and therapeutic implications: a population-based analysis.
Topics: Administration, Oral; Analysis of Variance; Brazil; Delivery of Health Care; Diabetes Mellitus; Drug | 2012 |
Glyburide ameliorates motor coordination and glucose homeostasis in a child with diabetes associated with the KCNJ11/S225T, del226-232 mutation.
Topics: Child; Diabetes Complications; Diabetes Mellitus; Diabetic Neuropathies; Epilepsy; Glyburide; Glycat | 2012 |
Improved long-term glucose control in neonatal diabetes mellitus after early sulfonylurea allergy.
Topics: ATP-Binding Cassette Transporters; Blood Glucose; Child; Diabetes Mellitus; Female; Glyburide; Glyca | 2012 |
Permanent neonatal diabetes mellitus due to KCNJ11 mutation in a Portuguese family: transition from insulin to oral sulfonylureas.
Topics: Administration, Oral; Adult; Blood Glucose; Child; Diabetes Mellitus; Family; Female; Glyburide; Gly | 2012 |
The diagnosis of neonatal diabetes in a mother at 25 years of age.
Topics: Adult; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Mothers | 2012 |
Switch to anaerobic glucose metabolism with NADH accumulation in the beta-cell model of mitochondrial diabetes. Characteristics of betaHC9 cells deficient in mitochondrial DNA transcription.
Topics: Anaerobiosis; Animals; Calcium; Cell Count; Cells, Cultured; Diabetes Mellitus; DNA, Mitochondrial; | 2002 |
Keratic precipitates and iris nodules after uneventful phacoemulsification in diabetic patients.
Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Corneal Diseases; Diabetes Complications; Diabetes Me | 2002 |
Diabetes mellitus impairs vasodilation to hypoxia in human coronary arterioles: reduced activity of ATP-sensitive potassium channels.
Topics: Adenosine Triphosphate; Age Factors; Arterioles; Bradykinin; Coronary Vessels; Diabetes Mellitus; Fe | 2003 |
Comparison of the effects of glimepiride and glibenclamide on adipose tissue tumour necrosis factor-alpha mRNA expression and cellularity.
Topics: Adipose Tissue; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type | 2004 |
The effect of medicinal plants of Islamabad and Murree region of Pakistan on insulin secretion from INS-1 cells.
Topics: Animals; Cell Line; Diabetes Mellitus; Dose-Response Relationship, Drug; Flowers; Fruit; Glyburide; | 2004 |
Glibenclamide treatment in permanent neonatal diabetes mellitus due to an activating mutation in Kir6.2.
Topics: Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Male; Mutation; Potassium | 2004 |
Diabetes mellitus in a domesticated Spanish mustang.
Topics: Animals; Area Under Curve; Blood Glucose; Diabetes Mellitus; Female; Glyburide; Horse Diseases; Hors | 2005 |
In vitro and in vivo evaluation of novel glibenclamide derivatives as imaging agents for the non-invasive assessment of the pancreatic islet cell mass in animals and humans.
Topics: Animals; ATP-Binding Cassette Transporters; Diabetes Mellitus; Fluorine Radioisotopes; Glyburide; Hu | 2005 |
Atypical diabetes associated with inclusion formation in the R6/2 mouse model of Huntington's disease is not improved by treatment with hypoglycaemic agents.
Topics: Administration, Oral; Animals; Behavior, Animal; Diabetes Mellitus; Disease Models, Animal; Exocytos | 2005 |
Transient neonatal diabetes mellitus is associated with a recurrent (R201H) KCNJ11 (KIR6.2) mutation.
Topics: Adult; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant; Insulin; Mutation; | 2005 |
Mitochondrial dysfunction as the cause of the failure to precondition the diabetic human myocardium.
Topics: Adenosine; Adrenergic alpha-Agonists; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitu | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
Switching from insulin to oral sulfonylureas in patients with diabetes due to Kir6.2 mutations.
Topics: ATP-Binding Cassette Transporters; Cohort Studies; Diabetes Mellitus; Female; Glyburide; Glycated He | 2006 |
ATP-sensitive potassium channels--neonatal diabetes mellitus and beyond.
Topics: ATP-Binding Cassette Transporters; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Infant | 2006 |
Improved motor development and good long-term glycaemic control with sulfonylurea treatment in a patient with the syndrome of intermediate developmental delay, early-onset generalised epilepsy and neonatal diabetes associated with the V59M mutation in the
Topics: Amino Acid Substitution; Blood Glucose; Developmental Disabilities; Diabetes Mellitus; Epilepsy; Fol | 2006 |
Sulfonylurea treatment in young children with neonatal diabetes: dealing with hyperglycemia, hypoglycemia, and sick days.
Topics: Blood Glucose; Child, Preschool; Diabetes Mellitus; Female; Glyburide; Health Status; Humans; Hyperg | 2007 |
Sulfonylurea-responsive diabetes in childhood.
Topics: Adult; Child; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Infant, Newborn; Ma | 2007 |
A novel mutation causing DEND syndrome: a treatable channelopathy of pancreas and brain.
Topics: Animals; Anticonvulsants; Cell Membrane; Child, Preschool; Developmental Disabilities; Diabetes Mell | 2007 |
Sulfonylurea therapy in two Korean patients with insulin-treated neonatal diabetes due to heterozygous mutations of the KCNJ11 gene encoding Kir6.2.
Topics: Base Sequence; C-Peptide; Diabetes Mellitus; DNA Mutational Analysis; Female; Glyburide; Glycated He | 2007 |
Sulfonylurea improves CNS function in a case of intermediate DEND syndrome caused by a mutation in KCNJ11.
Topics: Child; Child, Preschool; Developmental Disabilities; Diabetes Mellitus; DNA Mutational Analysis; Fem | 2007 |
Outpatient transition of an infant with permanent neonatal diabetes due to a KCNJ11 activating mutation from subcutaneous insulin to oral glyburide.
Topics: Birth Weight; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Female; Glybu | 2008 |
Atrial flutter and myocardial infarction-like ECG changes as manifestations of left ventricle involvement from lung carcinoma.
Topics: Antihypertensive Agents; Antineoplastic Combined Chemotherapy Protocols; Atrial Flutter; Carboplatin | 2008 |
Impact of fixed-dose combination drugs on adherence to prescription medications.
Topics: Adolescent; Adult; Aged; Diabetes Mellitus; Drug Administration Schedule; Drug Combinations; Drug Th | 2008 |
Clinical significance of altered insulin sensitivity in diabetes mellitus assessed by glucose, insulin, and somatostatin infusion.
Topics: Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diet, Diabetic; Fasting; Glucose; Glyburi | 1981 |
[Effect of beta receptor blockers on carbohydrate metabolism].
Topics: Adrenergic beta-Antagonists; Aged; Blood Glucose; Carbohydrate Metabolism; Coronary Disease; Diabete | 1981 |
[Study of the interaction between glibenclamide and zimelidine in acute and chronic administration].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Drug Interactions; Drug Therapy, Combination; Female; | 1983 |
Effect of dietary fiber, glucomannan, on absorption of sulfonylurea in man.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Dietary Fiber; Glyburide; Humans; Intestinal Absorption; Ma | 1983 |
[1-year study on the effect of guar on carbohydrate and lipid metabolism as well as tolerability in ambulatory glibenclamide-treated patients with diabetes mellitus].
Topics: Blood Glucose; Body Weight; Carbohydrate Metabolism; Combined Modality Therapy; Diabetes Mellitus; D | 1983 |
[Diabetes mellitus].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Insulin; Metformin | 1983 |
Glyburide and glipizide.
Topics: Diabetes Mellitus; Glipizide; Glyburide; Humans; Sulfonylurea Compounds | 1984 |
[The effects of glibenclamide and insulin on plasma high density lipoproteins in diabetics (author's transl)].
Topics: Adolescent; Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus; Female; Glyburide; Hemoglobi | 1980 |
Serum glibenclamide in diabetic patients, and influence of food on the kinetics and effects of glibenclamide.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Eating; Glyburide; | 1980 |
[Behavior of lactate and pyruvate in diabetics treated with a combination of fenformin and sulfonylurea in varying doses. I].
Topics: Adult; Aged; Chlorpropamide; Diabetes Mellitus; Diabetic Ketoacidosis; Drug Combinations; Female; Gl | 1980 |
The effect of improvement in diabetic control on plasma and whole blood viscosity.
Topics: Adolescent; Adult; Blood; Blood Glucose; Diabetes Mellitus; Female; Glipizide; Glyburide; Hemoglobin | 1980 |
[Hypersensitivity vasculitis and granulomatous hepatitis induced by glybenclamide: a case report (author's transl)].
Topics: Diabetes Mellitus; Drug Hypersensitivity; Glyburide; Granuloma; Hepatitis; Humans; Male; Middle Aged | 1980 |
Stimulation of residual insulin secretion by glibenclamide in insulin dependent diabetics.
Topics: Adolescent; Adult; C-Peptide; Diabetes Mellitus; Female; Glyburide; Humans; Insulin; Insulin Secreti | 1980 |
Kinetics-effect relations of glipizide and other sulfonylureas.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus; Dose-Response Relationship, Drug; Fasting; Feeding | 1980 |
Diurnal pattern of plasma insulin and blood glucose during glibenclamide and glipizide therapy in elderly diabetics.
Topics: Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus; Female; Glipizide; Glyburide; Humans; Insu | 1980 |
The effect of glibenclamide on the glucose and insulin profile in maturity onset diabetics following both acute and long term treatment.
Topics: Aged; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Insulin; Kinetics; Male; Middle Aged; Tim | 1980 |
Pregnancy in established non-insulin-dependent diabetics. A five-and-a-half year study at Groote Schuur Hospital.
Topics: Diabetes Mellitus; Female; Glyburide; Humans; Infant Mortality; Insulin; Labor, Induced; Metformin; | 1980 |
The hypothalamic-pituitary axis in diabetes mellitus.
Topics: Adult; Diabetes Mellitus; Follicle Stimulating Hormone; Glyburide; Gonadotropin-Releasing Hormone; H | 1980 |
The pharmacology of sulfonylureas.
Topics: Acetohexamide; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Glyburide; Humans; Insulin; Sulfony | 1981 |
[Haemoglobin A1c concentration in newly detected diabetes mellitus (author's transl)].
Topics: Aged; Blood Glucose; Diabetes Mellitus; Female; Glyburide; Glycoproteins; Hemoglobins, Abnormal; Hum | 1981 |
Hormonal and metabolic effects of chlorpropamide, glibenclamide and placebo in a cross-over study in diabetics not controlled by diet alone.
Topics: Adult; Aged; Body Weight; Chlorpropamide; Diabetes Mellitus; Diet, Diabetic; Fatty Acids, Nonesterif | 1981 |
Lipoprotein patterns in diet, sulphonylurea, and insulin treated diabetics.
Topics: Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Human | 1981 |
IRI-secretion in MOD with and without SU (5 year control).
Topics: Blood Glucose; Diabetes Mellitus; Glucagon; Glyburide; Humans; Insulin; Middle Aged; Tolbutamide | 1980 |
Sulphonylurea and insulin combination in the treatment of diabetes.
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glyburide; Humans; Insulin | 1981 |
Intrahepatic cholestasis and cutaneous bullae associated with glibenclamide therapy.
Topics: Blister; Cholestasis, Intrahepatic; Diabetes Mellitus; Glyburide; Humans; Male; Middle Aged | 1981 |
[Insulin plus sulphonyl-urea compounds in the treatment of diabetes mellitus of the maturity-onset type (author's transl)].
Topics: Aged; Diabetes Mellitus; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Male; Middle | 1982 |
Comparison of diurnal serum insulin levels during short term treatments with sulfonylurea and with insulin in non-insulin dependent diabetes.
Topics: Adult; Aged; Blood Glucose; Circadian Rhythm; Diabetes Mellitus; Female; Glyburide; Humans; Insulin; | 1982 |
[Studies on platelets in diabetic patients. Part 1: Platelet aggregation, volume and microviscosity in diabetes mellitus treated with diet, antidiabetic agent and insulin (author's transl)].
Topics: Blood Viscosity; Blood Volume; Diabetes Mellitus; Female; Glyburide; Humans; Insulin; Male; Middle A | 1981 |
The effects of glibenclamide and insulin on plasma high density lipoprotein in diabetics.
Topics: Cholesterol; Diabetes Mellitus; Glyburide; Humans; Insulin; Lipoproteins, HDL; Lipoproteins, LDL; Li | 1981 |
The effect of acebutolol and propranolol on the hypoglycaemic action of glibenclamide.
Topics: Acebutolol; Adult; Aged; Blood Glucose; Diabetes Mellitus; Drug Interactions; Female; Glyburide; Hum | 1982 |
Improved effect of glibenclamide on administration before breakfast.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Drug Administration Schedule; Fasting; Female; Food; Glybur | 1982 |
Branched-chain amino acids and alanine as indices of the metabolic control in type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetic patients.
Topics: Alanine; Amino Acids, Branched-Chain; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; F | 1982 |
The inhibition of cancer cell stickiness, a model for investigation of platelet aggregation inhibitors in vivo. Effect of the sulfonyl urea derivatives, glibenclamide, gliclazide, and HB180, as well as the carboxylic acid derivative, meglitinide.
Topics: Animals; Benzamides; Carcinoma 256, Walker; Cell Aggregation; Diabetes Mellitus; Gliclazide; Glyburi | 1982 |
[Effect of glibenclamide therapy on carbohydrate and lipid metabolism and insulin secretion in patients with glucose tolerance disorders : a 5-year study].
Topics: Blood Glucose; Body Weight; Diabetes Mellitus; Glucose Tolerance Test; Glyburide; Humans; Insulin; I | 1981 |
Chlorpropamide and glibenclamide serum concentrations in hospitalized patients.
Topics: Aged; Body Weight; Chlorpropamide; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Glyb | 1982 |
[Clinical effects of low-dose glibenclamide (1.25 mg) on type-II diabetes].
Topics: Adult; Aged; Diabetes Mellitus; Female; Glyburide; Humans; Male; Middle Aged | 1982 |
The high prevalence of the diabetic patients with a mutation in the mitochondrial gene in Japan.
Topics: Adolescent; Adult; Base Sequence; Diabetes Mellitus; DNA, Mitochondrial; Female; Glucose Tolerance T | 1994 |
[Hypoglycemia associated with angiotensin-converting enzyme inhibitors].
Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Diabetes Complications; Di | 1993 |
The pharmacokinetics and pharmacodynamics of 12 weeks of glyburide therapy in obese diabetics.
Topics: Aged; Blood Glucose; Body Mass Index; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Femal | 1993 |
Serious, prolonged hypoglycaemia with glibenclamide in a patient with Mendenhall's syndrome.
Topics: Abnormalities, Multiple; Adult; Diabetes Mellitus; Glyburide; Humans; Hyperplasia; Hypoglycemia; Hyp | 1993 |
Bedtime insulin added to daytime sulfonylureas improves glycemic control in uncontrolled type II diabetes.
Topics: Adult; Aged; Diabetes Mellitus; Diabetes Mellitus, Type 2; Drug Therapy, Combination; Glipizide; Gly | 1993 |
Nurse liability for dispensing meds "as ordered". Case in point: Navarro v. George 615A. 2d 890--PA (1992).
Topics: Chlorpropamide; Diabetes Mellitus; Glyburide; Humans; Male; Malpractice; Medication Errors; Nursing | 1993 |
Correction of hyperinsulinemia by glyburide treatment in nondiabetic patients with thalassemia major.
Topics: Adolescent; Adult; beta-Thalassemia; Child; Diabetes Mellitus; Female; Glucose Tolerance Test; Glybu | 1993 |
Rat inwardly rectifying potassium channel Kir6.2: cloning electrophysiological characterization, and decreased expression in pancreatic islets of male Zucker diabetic fatty rats.
Topics: Adenosine Triphosphate; Amino Acid Sequence; Animals; Base Sequence; Cattle; Cell Line; Cloning, Mol | 1996 |
Possible interaction between cyclosporine and glibenclamide in posttransplant diabetic patients.
Topics: Adult; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Diabetes Mellitus; Drug | 1996 |
Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited.
Topics: Administration, Oral; Aged; Diabetes Mellitus; Female; Glipizide; Glyburide; Heart Atria; Humans; Hy | 1997 |
Atypical ketoacidosis in type 2 diabetes.
Topics: Adult; Ambulatory Care; Clinical Protocols; Diabetes Complications; Diabetes Mellitus; Diabetes Mell | 1998 |
Commercially sponsored supplements.
Topics: Acarbose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agents; Peri | 1998 |
Risk factors for steroid diabetes in rheumatic patients.
Topics: Administration, Oral; Adolescent; Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, N | 1998 |
Bone amyloidoma in a diabetic patient with morbid obesity.
Topics: Amyloidosis; Bone Diseases; Diabetes Complications; Diabetes Mellitus; Diabetes Mellitus, Type 2; Gl | 1999 |
Long-term effects of glibenclamide and nateglinide upon pancreatic islet function in normal and diabetic rats.
Topics: Animals; Blood Glucose; Cyclohexanes; Diabetes Mellitus; Female; Glyburide; Hypoglycemic Agents; Ins | 1999 |
Diabetes as a result of atypical anti-psychotic drugs--a report of three cases.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Depressive Disorder; Diabetes Mellitus; Gly | 2000 |
[Proliferative activity of the gastric epithelium: changes due to therapy in patients with association of gastric ulcer and diabetes mellitus].
Topics: Adult; Age Factors; Aged; Data Interpretation, Statistical; Diabetes Complications; Diabetes Mellitu | 2001 |
Oral hypoglycemics and azoles: an important drug interaction.
Topics: Antifungal Agents; Candidiasis; Diabetes Mellitus; Drug Interactions; Female; Fluconazole; Glyburide | 2001 |
Diabetes mellitus and cystic fibrosis: comparison of clinical parameters in patients treated with insulin versus oral glucose-lowering agents.
Topics: Child; Child, Preschool; Cystic Fibrosis; Diabetes Complications; Diabetes Mellitus; Female; Glyburi | 2001 |
Insulinotropic activity of the imidazoline derivative RX871024 in the diabetic GK rat.
Topics: Adenosine Triphosphate; Animals; Calcium; Diabetes Mellitus; Diglycerides; Glucose; Glyburide; Hypog | 2002 |
Letter: Treatment of maturity-onset diabetes.
Topics: Blood Glucose; Chlorpropamide; Diabetes Mellitus; Diet, Diabetic; Glyburide; Humans | 1975 |
Letter: Treatment of maturity-onset diabetes.
Topics: Adult; Age Factors; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Diet, Diabe | 1975 |
Letter: Treatment of maturity-onset diabetes.
Topics: Adult; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Glyburide; Humans | 1975 |
[Diurnal variations in glucose tolerance in normal subjects and changes induced by oral glibenclamide].
Topics: Adult; Blood Glucose; Circadian Rhythm; Diabetes Mellitus; Glucose Tolerance Test; Glyburide; Growth | 1978 |
[Behavior of blood sugar and insulin in diabetics at the suspension of glibenclamide therapy].
Topics: Adult; Blood Glucose; Diabetes Mellitus; Female; Glyburide; Humans; Insulin; Male; Middle Aged | 1978 |
Insulin secretion, carbohydrate tolerance, fat metabolism and body weight in maturity onset diabetics requiring various methods of therapy.
Topics: Adult; Aged; Body Weight; Cholesterol; Diabetes Mellitus; Diet, Diabetic; Fatty Acids, Nonesterified | 1978 |
Diabetic microangiopathy in KK mice. III. Effect of prolonged glyburide treatment on glomerulosclerosis.
Topics: Animals; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Glomerulonephritis; Glomeruloscle | 1978 |
Comparative effects of two doses of glibenclamide upon metabolic rhythms in maturity-onset diabetics.
Topics: Aged; Alanine; Blood Glucose; Circadian Rhythm; Diabetes Mellitus; Fatty Acids, Nonesterified; Glybu | 1978 |
[Controlled clinical study of the therapeutic action of 2 combinations of glibenclamide and phenformin].
Topics: Aged; Blood Glucose; Diabetes Mellitus; Drug Combinations; Drug Evaluation; Female; Glyburide; Human | 1978 |
Increased insulin sensitivity and cellular insulin binding in obese diabetics following treatment with glibenclamide.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Glucose Tolerance Test; Glyburide; Humans; In | 1979 |
[Treatment of adult diabetes with semi-euglucon (author's transl)].
Topics: Aged; Body Weight; Diabetes Mellitus; Diet, Reducing; Drug Evaluation; Female; Glyburide; Humans; Ma | 1979 |
Radioimmunoassay of glibenclamide.
Topics: Animals; Diabetes Mellitus; Dogs; Glyburide; Humans; Radioimmunoassay | 1979 |
Effect of two sulphonylureas on the dose kinetics of glucose-induced insulin release in normal and diabetic subjects.
Topics: Adult; Diabetes Mellitus; Dose-Response Relationship, Drug; Female; Glucose; Glucose Tolerance Test; | 1979 |
Glibenclamide, acute/long-term response in M.O. diabetics.
Topics: Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Insulin; Male; Time Factors | 1979 |
The effect of glibenclamide treatment on the insulin and glucagon responses to oral glucose and galactose in maturity onset diabetics.
Topics: Aged; Diabetes Mellitus; Female; Galactose; Glucagon; Glucose Tolerance Test; Glyburide; Humans; Ins | 1979 |
[Clinical significance of the radioimmunological determination of C-peptide (author's transl)].
Topics: Adult; Arginine; C-Peptide; Diabetes Mellitus; Fasting; Glyburide; Humans; Insulin; Middle Aged; Pep | 1979 |
Diabetes newly diagnosed during pregnancy: A 4-year study at Groote Schuur Hospital.
Topics: Adolescent; Adult; Birth Weight; Black or African American; Black People; Delivery, Obstetric; Diabe | 1979 |
Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents administered i.v.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glipizide; Glyburide; H | 1976 |
[Daily profile of the blood level of sulfonylurea and metabolic parameters in adult diabetics under monotherapy with various sulfonylurea compounds and comparable metabolic adjustment].
Topics: Adult; Diabetes Mellitus; Glyburide; Humans; Sulfonylurea Compounds | 1976 |
Cholesterol metabolism in hypertriglyceridaemia and the effects of treatment.
Topics: Adult; Alcohol Drinking; Bile Acids and Salts; Cholesterol; Chylomicrons; Diabetes Complications; Di | 1975 |
[Diabetes: new drugs?].
Topics: Biguanides; Diabetes Mellitus; Glipizide; Glyburide; Humans; Hypoglycemic Agents; Insulin; Sulfonylu | 1976 |
Modification of diuresis in the rat by chlorpropamide, glibenclamide and tolbutamide.
Topics: Administration, Oral; Animals; Body Water; Chlorpropamide; Diabetes Mellitus; Diuresis; Glyburide; H | 1975 |
Behaviour of glibenclamide on repeated administration to diabetic patients.
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Eating; Glyburide; Humans; Insulin; Models, | 1977 |
Side effects of therapy in diabetes evaluated by a self-administered questionnaire.
Topics: Chlorpropamide; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Humans; Hypoglycemic Agents; I | 1977 |
[Acute thrombocytopenic purpura following glibenclamide medication].
Topics: Acute Disease; Aged; Diabetes Mellitus; Female; Glyburide; Humans; Purpura, Thrombocytopenic | 1977 |
Comparative effects of phenformin, metformin and glibenclamide on metabolic rhythms in maturity-onset diabetics.
Topics: Aged; Alanine; Blood Glucose; Circadian Rhythm; Diabetes Mellitus; Female; Gluconeogenesis; Glyburid | 1977 |
Glibenclamide and nocturia.
Topics: Adult; Age Factors; Aged; Diabetes Mellitus; Glyburide; Humans; Middle Aged; Urination Disorders | 1977 |
[Treatment of overweight diabetics with a combination of glibenclamide and phenformin].
Topics: Adult; Diabetes Mellitus; Drug Combinations; Female; Glyburide; Humans; Male; Middle Aged; Obesity; | 1977 |
[Oral antidiabetics and the heart: value of glibenclamide].
Topics: Diabetes Complications; Diabetes Mellitus; Glyburide; Heart; Humans; Hypoglycemic Agents; Myocardial | 1977 |
[Clinico-statistical studies of the use of oral hypoglycemic agents in the therapy of diabetes: critical evaluation of their effectiveness and tolerance].
Topics: Adult; Aged; Chlorpropamide; Diabetes Mellitus; Drug Evaluation; Drug Therapy, Combination; Female; | 1977 |
Potentiation of glibenclamide-induced insulin release by calcium infusion.
Topics: Adult; Aged; Blood Glucose; Calcium; Diabetes Mellitus; Female; Glyburide; Humans; Infusions, Parent | 1977 |
[Doctors, diabetes and the danger of death].
Topics: Aged; Diabetes Mellitus; Diabetic Coma; Female; Glyburide; Humans; Hypoglycemia | 1977 |
[Human C-peptide. Part III: dynamics of secretion of beta-cells in adult diabetics following glibenclamide-glucose i.v. (human C-peptide III) (author's transl)].
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus; Female; Glucose; Glyburide; Humans; Injections, Intraveno | 1978 |
[Biguanides in the treatment of obesity].
Topics: Biguanides; Diabetes Mellitus; Drug Therapy, Combination; Glyburide; Humans; Insulin; Obesity; Phenf | 1978 |
Insulin therapy in relation to circulating C-peptide levels.
Topics: Adult; Aged; C-Peptide; Diabetes Mellitus; Female; Glucose Tolerance Test; Glyburide; Humans; Insuli | 1978 |
[14C-Glibenclamide concentrations in serum and 14C-glibenclamide urine excretion in diabetic patients with simultaneous determination of blood glucose and insulin (author's transl)].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Female; Glyburide; Humans; Insulin; Male; Methods; Mi | 1978 |
[Daily curves of blood sugar and serum insulin after treatment with various combinations of glibenclamide and phenformin].
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Drug Combinations; Female; Glyburide; Humans; Insulin | 1975 |
Increased disaccharidase activity in human diabetics.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Disaccharidases; Feces; Female; Galactosidases; Glucosidase | 1975 |
[Effect of methylpyrazole-carboxylic acid on carbohydrate and lipid metabolisms in patients with diabetes mellitus].
Topics: Aged; Blood Glucose; Carbutamide; Cholesterol; Diabetes Mellitus; Drug Evaluation; Fatty Acids, None | 1975 |
Myocardial infarction in diabetics.
Topics: Administration, Oral; Adult; Aged; Chlorpropamide; Coronary Care Units; Diabetes Complications; Diab | 1975 |
[Mechanism of action of gliquidone (author's transl)].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Glyburide; Hypog | 1975 |
[Effect of gliquidone and glibenclamide following oral administration].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Dose-Response Relationship, Drug; Fasting; F | 1975 |
[The importance of serum insulin determination in the diagnosis and treatment of diabetes mellitus (author's transl)].
Topics: Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diet Therapy; Dose-Response Relationshi | 1975 |
[Transient cerebral insult in hypoglycemias].
Topics: Age Factors; Aged; Cerebrovascular Disorders; Diabetes Mellitus; Diabetic Coma; Glyburide; Humans; H | 1976 |
[Peroral therapy of diabetes mellitus].
Topics: Administration, Oral; Adult; Aged; Biguanides; Diabetes Mellitus; Drug Therapy, Combination; Glyburi | 1975 |
Clinical experience with glibenclamide in long-term treatment of diabetes mellitus.
Topics: Adult; Aged; Diabetes Mellitus; Drug Evaluation; Drug Therapy, Combination; Female; Glyburide; Human | 1976 |
In vivo cytogenetic activity of sulphonylurea drugs in man.
Topics: Adult; Chlorpropamide; Chromosome Aberrations; Chromosome Deletion; Diabetes Mellitus; Female; Glybu | 1976 |
Comparative study of glibenclamide & chlorpropamide in newly diagnosed maturity onset diabetics.
Topics: Adult; Aged; Blood Glucose; Body Weight; Chlorpropamide; Diabetes Mellitus; Drug Evaluation; Female; | 1976 |
[Radioimmunological determination of insulin in patients with manifest diabetes mellitus as a guide for the planning of therapy (author's transl)].
Topics: Biguanides; Blood Glucose; Body Weight; Diabetes Mellitus; Female; Glucose Tolerance Test; Glyburide | 1976 |
[Hypoglycemic complications of oral drug therapy of diabetes mellitus. 21 cases].
Topics: Age Factors; Aged; Diabetes Mellitus; Diabetic Coma; Drug Interactions; Female; Gliclazide; Glyburid | 1976 |
[Diabetes therapy in relation to insulin secretion].
Topics: Diabetes Mellitus; Glyburide; Humans; Insulin; Insulin Secretion | 1975 |
[Effect of tolbutamide and glibenclamide on glucagon secretion in subjects with normal metabolism and in diabetics].
Topics: Adult; Diabetes Mellitus; Glucagon; Glyburide; Humans; Male; Tolbutamide | 1975 |
[Metabolic control and insulin secretion in diabetic patients treated with glibenclamide-phenformin combination].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Female; Glyburide; Humans; Insulin; Insulin Secretion; | 1975 |
Glyburide.
Topics: Chlorpropamide; Diabetes Mellitus; Drug Evaluation; Glyburide; Humans; Hypoglycemia; Insulin; Insuli | 1976 |
[Changes in lipid metabolism in a case of associated primary hypothyroidism, obesity and diabetes mellitus].
Topics: Aged; Cholesterol; Clofibrate; Diabetes Complications; Diabetes Mellitus; Female; Glyburide; Humans; | 1976 |
Blood ketone body disappearance rate in diabetics and normals after rapid infusion of dl-3-hydroxybutyrate. Studies before and after diabetic treatment.
Topics: Acetoacetates; Adolescent; Adult; Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 1; | 1976 |
Human C-peptide. Part II: Clinical studies.
Topics: C-Peptide; Chromatography, Gel; Diabetes Mellitus; Diabetes Mellitus, Type 1; Glucose; Glyburide; Hu | 1976 |
[Clinical experience with the new Hungarian glibenclamide product (Gilemal)].
Topics: Blood Glucose; Diabetes Mellitus; Glyburide; Insulin | 1976 |
[Hypoglycaemic activity of centaurea aspera L (author's transl)].
Topics: Administration, Oral; Animals; Diabetes Mellitus; Diabetes Mellitus, Experimental; Female; Glyburide | 1976 |
[Effects of glibenclamide on blood lipid changes induced by oral lipid load in diabetic subjects].
Topics: Administration, Oral; Adult; Butter; Diabetes Mellitus; Dietary Fats; Female; Glyburide; Humans; Lip | 1976 |
[Re-evaluation of the action of salicylate on glucose and insulin blood levels in normal and diabetic subjects and possible interference with oral antidiabetic therapy].
Topics: Blood Glucose; Diabetes Mellitus; Drug Synergism; Glyburide; Humans; Insulin; Salicylates | 1976 |
[Value of fractionation in diabetology therapy and particularly for glibenclamide].
Topics: Diabetes Mellitus; Glyburide; Humans; Insulin | 1976 |
[C-peptide determination as a parameter for oral diabetes therapy].
Topics: Administration, Oral; Blood Glucose; C-Peptide; Diabetes Mellitus; Glyburide; Humans; Insulin; Pepti | 1976 |
Reduction of hyperinsulinemia by glyburide--scientific fact or advertising fiction?
Topics: Advertising; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Hyperinsulinism; Periodicals as To | 1992 |
Hypoglycemia presenting as hemiparesis in a diabetic patient.
Topics: Diabetes Complications; Diabetes Mellitus; Female; Glyburide; Hemiplegia; Humans; Hypoglycemia; Midd | 1992 |
Second generation oral hypoglycemic agents.
Topics: Administration, Oral; Cataract; Diabetes Mellitus; Glyburide; Humans; Hyperopia; Lens, Crystalline | 1991 |
Platelet adhesiveness and fibrinolytic activity in diabetes mellitus before and after therapy.
Topics: Adolescent; Adult; Aged; Child; Diabetes Mellitus; Female; Fibrinolysis; Glyburide; Humans; Insulin; | 1991 |
Diabetes prevention in BB rats by inhibition of endogenous insulin secretion.
Topics: Analysis of Variance; Animals; Blood Glucose; Diabetes Mellitus; Diazoxide; Glucose Tolerance Test; | 1991 |
[New oral antidiabetic agents].
Topics: Animals; Cyclohexanols; Diabetes Mellitus; Drug Evaluation; Gliclazide; Glyburide; Humans; Hypoglyce | 1990 |
Diabetic complete external ophthalmoplegia.
Topics: Aged; Diabetes Complications; Diabetes Mellitus; Facial Nerve; Facial Paralysis; Glyburide; Humans; | 1990 |
[Treatment of newly diagnosed type II diabetic patients with special reference to prescribing glibenclamide in low doses].
Topics: Aged; Blood Glucose; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Dose-Response Rel | 1989 |
Glucose stick misuse.
Topics: Blood Glucose; Diabetes Mellitus; Diagnostic Errors; Glyburide; Humans; Hypoglycemia; Insulin; Male; | 1986 |
[Antidiabetic drugs].
Topics: Biguanides; Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Insulin | 1986 |
Effect of glibenclamide on thyroid hormone metabolism in rats.
Topics: Animals; Diabetes Mellitus; Glyburide; Kidney; Liver; Male; Rats; Rats, Inbred Strains; Thyroid Horm | 1986 |
[Protracted hypoglycemia as a consequence of the secret taking of glibenclamide by a young female diabetic].
Topics: Adult; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemia; Self Medication | 1986 |
High-performance liquid chromatographic determination of glibenclamide in human plasma and urine.
Topics: Chromatography, High Pressure Liquid; Diabetes Mellitus; Glyburide; Humans; Kinetics; Spectrophotome | 1986 |
Psoriasiform drug eruption due to glibenclamide.
Topics: Betamethasone; Diabetes Mellitus; Drug Hypersensitivity; Female; Glyburide; Humans; Middle Aged; Pso | 1987 |
Effect of a sulfonylurea and insulin on energy expenditure in type II diabetes mellitus.
Topics: Blood Glucose; Blood Urea Nitrogen; C-Peptide; Diabetes Mellitus; Diabetes Mellitus, Type 2; Energy | 1988 |
[Insulin therapy of obese diabetic patients? Consequences for the evaluation of insulin secretion and metabolic behavior].
Topics: Combined Modality Therapy; Diabetes Mellitus; Diabetes Mellitus, Type 2; Diet, Diabetic; Energy Meta | 1987 |
[A case of hypoglycemia with a marked convulsive syndrome after intake of maninil].
Topics: Aged; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemia; Seizures | 1988 |
In vivo action of glibenclamide in obese subjects with mild type 2 (non-insulin dependent) diabetes.
Topics: Adult; Blood Glucose; C-Peptide; Circadian Rhythm; Diabetes Mellitus; Diabetes Mellitus, Type 2; Fem | 1988 |
[Correlation between the levels of CA19-9 and fasting plasma glucose in a case of diabetes mellitus].
Topics: Aged; Antigens, Tumor-Associated, Carbohydrate; Blood Glucose; Diabetes Mellitus; Female; Glyburide; | 1988 |
Determination of glibenclamide, chlorpropamide and tolbutamide in plasma by high-performance liquid chromatography with ultraviolet detection.
Topics: Chlorpropamide; Chromatography, High Pressure Liquid; Diabetes Mellitus; Dinitrofluorobenzene; Gas C | 1985 |
Dual actions of sulfonylureas and glyburide. Receptor and post-receptor effects.
Topics: Adipose Tissue; Animals; Cells, Cultured; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mel | 1985 |
Apolipoproteins in diabetes mellitus.
Topics: Adult; Apolipoproteins; Bezafibrate; Diabetes Mellitus; Diabetes Mellitus, Type 1; Diabetes Mellitus | 1985 |
Clinical experience with Glibenclamide--Daonil.
Topics: Aged; Biguanides; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Insulin; Male; | 1971 |
[Thyroid gland function of patients with diabetes in long-term use of glibornuride].
Topics: Camphanes; Carbutamide; Diabetes Mellitus; Female; Glyburide; Goiter; Humans; Hypoglycemic Agents; M | 1972 |
Letter: Ring stains and diabetes.
Topics: Diabetes Mellitus; Female; Glyburide; Humans; Skin Manifestations; Sulfhydryl Compounds; Sulfides | 1974 |
Different amounts of insulin secretion following an equal total decrease of blood glucose as an indication of possible extrapancreatic activities of different sulfonylurea drugs.
Topics: Animals; Antigens; Autoanalysis; Blood Glucose; Camphanes; Computers; Diabetes Mellitus; Dogs; Fasti | 1973 |
[Experiences with glibenclamide therapy of diabetes].
Topics: Diabetes Mellitus; Glyburide; Humans | 1973 |
[Maximum dosage for oral antidiabetics].
Topics: Biguanides; Diabetes Mellitus; Glyburide; Humans | 1973 |
Efficacy of glibenclamide in maturity-onset diabetics as maintenance therapy.
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Body Weight; Diabetes Mellitus; Female; Follow-Up | 1973 |
[Insulin liberation by blood sugar decreasing sulfonamides and by glucose in adult diabetic patients].
Topics: Adult; Azepines; Blood Glucose; Diabetes Mellitus; Drug Interactions; Fatty Acids, Nonesterified; Gl | 1972 |
Observations of the mechanism of action of the sulfonylureas under clinical conditions.
Topics: Adult; Aged; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Fasting; Female; Glyburide; Humans; H | 1973 |
Glucose, FFA, IRI and GH response to I.V. glibenclamide.
Topics: Antigens; Blood Glucose; Diabetes Mellitus; Fasting; Fatty Acids, Nonesterified; Female; Glyburide; | 1973 |
[Preliminary clinical experiences and problems of long-term therapy of diabetes mellitus using 2nd generation sulfonylurea derivatives (glibenclamide)].
Topics: Diabetes Mellitus; Drug Resistance; Glyburide; Humans; Insulin; Long-Term Care; Middle Aged; Sulfony | 1973 |
[Euglucon in ambulatory practice].
Topics: Adolescent; Adult; Aged; Ambulatory Care; Child; Child, Preschool; Diabetes Mellitus; Drug Evaluatio | 1973 |
The scope of oral glibenclamide in the non-ketotic young diabetics.
Topics: Administration, Oral; Adolescent; Adult; Blood Glucose; Diabetes Mellitus; Drug Therapy, Combination | 1973 |
New drugs and research: glybenclamide (Euglucon).
Topics: Animals; Diabetes Mellitus; Glyburide; Humans | 1973 |
Experience with glibenclamide.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Fatty Acids, Nonesterified; Glyburide; Growth Hormone | 1973 |
[Secretion of insulin under the influence of sulfonylurea derivates (SH)].
Topics: Animals; Blood Glucose; Diabetes Mellitus; Glucose Tolerance Test; Glyburide; Humans; Insulin; Insul | 1973 |
[A comparison of intravenous tolbutamide and insulin administration during and after operation in patients with maturity-onset diabetes (author's transl)].
Topics: Administration, Oral; Age Factors; Aged; Anesthesia, General; Blood Glucose; Carbohydrates; Carbutam | 1974 |
An open comparative study of the efficacy and tolerance of a new antidiabetic agent: glipizide.
Topics: Blood Glucose; Chlorpropamide; Cyclohexanes; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; G | 1973 |
[Treatment of diabetes with euglucon 5 in a hospital for the aged (author's transl)].
Topics: Age Factors; Aged; Blood Glucose; Diabetes Mellitus; Diet Therapy; Diet, Diabetic; Drug Tolerance; F | 1973 |
[Use of glibenclamide in different forms of diabetes mellitus].
Topics: Adult; Aged; Diabetes Mellitus; Drug Therapy, Combination; Glyburide; Humans; Insulin; Middle Aged | 1973 |
[Chlorpropamide, thiazides and congestive heart failure].
Topics: Aged; Chlorpropamide; Diabetes Mellitus; Diuresis; Diuretics; Glyburide; Heart Failure; Humans; Hydr | 1974 |
[Combined intravenous glucose-glibenclamide load as test for prediction of success of oral longtime therapy of adult diabetes with glibenclamide].
Topics: Diabetes Mellitus; Glucose Tolerance Test; Glyburide; Humans; Insulin; Time Factors | 1973 |
[Longtime effect of blood sugar decreasing sulfonamides on glucose tolerance and insulin secretion in adult diabetic patients].
Topics: Diabetes Mellitus; Glucose Tolerance Test; Glyburide; Humans; Insulin; Insulin Secretion; Time Facto | 1973 |
Longterm clinical study with glibenclamide.
Topics: Adult; Aged; Diabetes Mellitus; Female; Follow-Up Studies; Glyburide; Humans; Long-Term Care; Male; | 1973 |
Editorial: Of what measures are second generation suphonylureas?
Topics: Diabetes Mellitus; Drug Evaluation; Glyburide; Humans | 1973 |
Computerized intravenous glybenclamide test in early diagnosis of diabetes mellitus.
Topics: Blood Glucose; Computers; Diabetes Mellitus; Diagnosis, Computer-Assisted; Glyburide; Humans; Inject | 1974 |
[Insulin secretion after administration of sulfonylurea in normal and diabetic subjects].
Topics: Diabetes Mellitus; Fatty Acids, Nonesterified; Female; Glucose Tolerance Test; Glyburide; Growth Hor | 1974 |
Clinical assessment of glybenclamide (daonil) in diabetes mellitus.
Topics: Chlorpropamide; Diabetes Mellitus; Female; Glyburide; Humans; Male; Tolbutamide | 1973 |
[Single intravenous glibenclamide-glucose loading as a prediction test (author's transl)].
Topics: Adult; Age Factors; Aged; Diabetes Mellitus; Female; Glucose Tolerance Test; Glyburide; Humans; Insu | 1974 |
[Clinico-therapeutic observations on the use of a new oral hypoglycemic drug (HB 419-297 R)].
Topics: Adult; Diabetes Mellitus; Drug Combinations; Female; Glyburide; Humans; Male; Middle Aged; Phenformi | 1974 |
[Modifications induced in post-prandial glycemia and insulinemia by treatment with glibenclamide and with a combination of glibenclamide and phenformin].
Topics: Blood Glucose; Diabetes Mellitus; Drug Combinations; Feeding Behavior; Female; Glyburide; Humans; In | 1974 |
[Pharmacologic study with glisoxepide and other blood sugar reducing sulfonamide derivatives in metabolically healthy subjects and diabetics].
Topics: Administration, Oral; Autoanalysis; Azepines; Blood Glucose; Depression, Chemical; Diabetes Mellitus | 1974 |
Mild familial diabetes with dominant inheritance.
Topics: Acetohexamide; Adolescent; Adult; Aged; Blood Glucose; Carbohydrates; Child; Chlorpropamide; Diabete | 1974 |
[Influence of a new oral hypoglycemic product (glibenclamide-phenformin) on some aspects of lipid metabolism].
Topics: Adult; Aged; Cholesterol; Diabetes Mellitus; Drug Combinations; Fatty Acids, Nonesterified; Female; | 1973 |
[Own observations on the action of glibenclamide (Daonil) in diabetes].
Topics: Adult; Aged; Diabetes Mellitus; Drug Tolerance; Female; Glyburide; Humans; Male; Middle Aged | 1974 |
[The following of a diabetic patient treated by Euglucan].
Topics: Blood Glucose; Diabetes Mellitus; Follow-Up Studies; Glyburide; Glycosuria; Humans | 1972 |
[The glibenclamide-phenformin combination in the therapy of diabetes mellitus].
Topics: Diabetes Mellitus; Drug Therapy, Combination; Glyburide; Humans; Insulin; Phenformin | 1974 |
Generalized hypersensitivity reaction and visceral arteritis with fatal outcome during glibenclamide therapy.
Topics: Acute Kidney Injury; Aged; Arteritis; Autopsy; Bronchopneumonia; Cholestasis; Diabetes Mellitus; Dru | 1974 |
[The glibenclamide-phenformin combination in the therapy of diabetes mellitus].
Topics: Adult; Aged; Biguanides; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Drug Combinations; Drug E | 1974 |
[Oral antidiabetic therapy with delayed-action glibenclamide and phenformin in fixed combination].
Topics: Adult; Aged; Blood Glucose; Carbutamide; Cholesterol; Delayed-Action Preparations; Diabetes Mellitus | 1974 |
[Therapeutic activity of a glibenclamide-phenformin association in maturity-onset diabetes].
Topics: Adult; Aged; Blood Glucose; Carbohydrates; Diabetes Mellitus; Drug Combinations; Drug Evaluation; Dr | 1974 |
Lacticacidosis, ketoacidosis, and hyperalaninaemia in a phenformintreated diabetic patient.
Topics: Acetoacetates; Alanine; Amitriptyline; Bicarbonates; Blood Glucose; Chlorpropamide; Diabetes Mellitu | 1974 |
Oral management of uncomplicated maturity onset diabetes.
Topics: Adult; Aged; Biguanides; Chlorpropamide; Diabetes Mellitus; Diet; Drug Combinations; Glucose Toleran | 1974 |
[Studies on the course of mass screening in discovered diabetic patients].
Topics: Adolescent; Adult; Aged; Biguanides; Child; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Hu | 1974 |
[Value of fractioning of the posology in oral treatment of diabetes mellitus].
Topics: Administration, Oral; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Mathematics | 1974 |
Proceedings: Half-life of phenprocoumarol (Marcumar R) during treatment with insulin and sulfonylureas in diabetics.
Topics: Benzyl Compounds; Blood Glucose; Coumarins; Diabetes Mellitus; Glyburide; Half-Life; Humans; Insulin | 1974 |
[Morphological changes in the pancreas and islands of Langerhans in rats during induced hyperglycemia and hypoglycemia].
Topics: Animals; Diabetes Mellitus; Glyburide; Hyperglycemia; Hypoglycemia; Islets of Langerhans; Pancreas; | 1974 |
[Hypoglycemic accidents during treatment with antidiabetic sulfamides. Apropos of 5 cases of hypoglycemic coma in aged subjects].
Topics: Aged; Blood Glucose; Carbutamide; Chlorpropamide; Diabetes Mellitus; Diabetic Coma; Diet Therapy; Fe | 1973 |
[The pancreatic beta-cell in the field of current diabetology].
Topics: Blood Glucose; Cyclic AMP; Diabetes Mellitus; Glucagon; Glucose Tolerance Test; Glyburide; Growth Ho | 1974 |
[Glibenclamide, a new oral antidiabetic].
Topics: Administration, Oral; Adult; Aged; Blood Glucose; Chlorpropamide; Diabetes Mellitus; Female; Glyburi | 1972 |
Blood coagulation in maturity--onset diabetics before and after treatment with glibenclamide.
Topics: Adult; Blood Coagulation; Diabetes Mellitus; Glyburide; Humans; Middle Aged; Sulfonylurea Compounds | 1972 |
[Advantages and hazards of oral antidiabetics].
Topics: Administration, Oral; Diabetes Mellitus; Diet Therapy; Glyburide; Humans; Hypoglycemia; Hypoglycemic | 1972 |
[Role of glibenclamide in the therapy of diabetes].
Topics: Adult; Chlorpropamide; Diabetes Mellitus; Evaluation Studies as Topic; Glyburide; Glycosuria; Humans | 1972 |
A dose equivalence study of glybenclamide (daonil)--a new hypoglycaemic agent.
Topics: Adult; Chlorpropamide; Diabetes Mellitus; Female; Glyburide; Humans; Male; Sulfonylurea Compounds; T | 1972 |
[Glibenclamide and diabetes mellitus. 1. Year's clinical experience].
Topics: Administration, Oral; Adult; Aged; Chlorpropamide; Diabetes Mellitus; Female; Glyburide; Humans; Mal | 1972 |
Experience with a new hypoglycemic agent, glibenclamide, HB 419 (Daonil) in diabetes mellitus.
Topics: Body Weight; Diabetes Mellitus; Drug Synergism; Glyburide; Humans; Insulin; Insulin Antibodies; Naus | 1972 |
[Clinical evaluation of glidiazinamide].
Topics: Blood Glucose; Cyclohexanes; Diabetes Mellitus; Evaluation Studies as Topic; Glucose Tolerance Test; | 1972 |
[Practical viewpoints on the treatment of diabetes with glibenclamide].
Topics: Administration, Oral; Adult; Aged; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Humans; Mal | 1972 |
Oral therapy in diabetes.
Topics: Acetohexamide; Administration, Oral; Animals; Chlorpropamide; Diabetes Mellitus; Diet Therapy; Evalu | 1972 |
[Oral diabetes therapy].
Topics: Administration, Oral; Biguanides; Diabetes Mellitus; Drug Combinations; Glyburide; Humans; Hypoglyce | 1972 |
[Attempts at substituting glibenclamide for insulin in the treatment of diabetes].
Topics: Adult; Aged; Diabetes Mellitus; Evaluation Studies as Topic; Female; Glyburide; Humans; Male; Middle | 1972 |
[Reaction of diabetic carbohydrate metabolism on the change from chlorpropamide to glibenclamide].
Topics: Adult; Chlorpropamide; Diabetes Complications; Diabetes Mellitus; Female; Glyburide; Humans; Hypogly | 1972 |
[Glibenclamide--a better antidiabetic agent?].
Topics: Aged; Blood Glucose; Body Weight; Chlorpropamide; Cholesterol; Diabetes Mellitus; Female; Glyburide; | 1972 |
Diabetes mellitus: the thin maturity-onset diabetic.
Topics: Acetohexamide; Body Weight; Chlorpropamide; Diabetes Mellitus; Glyburide; Humans; Hypoglycemia; Hypo | 1972 |
[Comparative clinical study of the oral hypoglycemic agent HB 419 or glibenclamide].
Topics: Administration, Oral; Adult; Diabetes Mellitus; Evaluation Studies as Topic; Female; Glyburide; Huma | 1972 |
Effect of glibenclamide on sugar transport by fed, starved and diabetic rat small intestine.
Topics: Animals; Carbohydrate Metabolism; Diabetes Mellitus; Diet; Galactose; Glucose; Glyburide; Ileum; In | 1973 |
[Hypoglycemia in glibenclamide therapy in diabetes].
Topics: Aged; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemia; Male; Phenylbutazone; Sulfaphenazo | 1973 |
[Testing a new antidiabetic (Glibenclamid) in hospitalized and ambulatory diabetics].
Topics: Administration, Oral; Adult; Aged; Ambulatory Care; Diabetes Mellitus; Drug Tolerance; Glyburide; Ho | 1970 |
Treatment with glibenclamide in maturity-onset diabetes mellitus.
Topics: Aged; Blood Glucose; Diabetes Complications; Diabetes Mellitus; Female; Follow-Up Studies; Glyburide | 1971 |
[Clinical study of glibenclamide, a new oral hypoglycemic agent].
Topics: Administration, Oral; Adolescent; Adult; Aged; Child; Diabetes Mellitus; Female; Glyburide; Humans; | 1971 |
[Diabetes mellitus in adults and glibenclamide. Effects on lipid, protein, and carbohydrate metabolism in diabetics].
Topics: Adult; Aged; Carbohydrate Metabolism; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Age | 1971 |
[Glibenclamide: its therapeutic effect in diabetes mellitus].
Topics: Adult; Diabetes Mellitus; Female; Glyburide; Humans; Hypoglycemic Agents; Male; Sulfonylurea Compoun | 1971 |
[Glibenclamide (Daonil Euglucon)].
Topics: Animals; Diabetes Mellitus; Glyburide; Humans; Mice; Sulfonylurea Compounds | 1971 |
[Incidence and severity of treatment-induced hypoglycemias in diabetics].
Topics: Aged; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Hemiplegia; Humans; Hypoglycemia; Insuli | 1971 |
Alcohol and glibenclamide.
Topics: Alcoholic Beverages; Diabetes Mellitus; Glyburide; Humans; Sulfonylurea Compounds | 1971 |
[HB 419 (glibenclamide) and possibilities of its combinations in the treatment of diabetes mellitus].
Topics: Diabetes Mellitus; Diabetes Mellitus, Type 1; Drug Synergism; Glyburide; Humans; Insulin; Sulfonylur | 1970 |
[Case of regeneration of the islands of Langerhans in a diabetic, following the use of glibenclamide].
Topics: Aged; Diabetes Mellitus; Female; Glyburide; Humans; Islets of Langerhans; Sulfonylurea Compounds | 1971 |
[Glibenclamide-phenformin in diabetics with failures after sulfonylureas].
Topics: Diabetes Mellitus; Drug Combinations; Female; Glyburide; Humans; Male; Middle Aged; Phenformin; Sulf | 1971 |
Treatment with glibenclamide in maturity-onset diabetes mellitus.
Topics: Age Factors; Aged; Diabetes Mellitus; Diet, Diabetic; Female; Glyburide; Humans; Hypoglycemic Agents | 1971 |
Pharmacodynamic aspects of tolbutamide, glibenclamide, glibornuride and glisoxepide. I. Dose response relations and repeated administration in diabetic subjects.
Topics: Adult; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Injections, Intravenous; Insulin; Insuli | 1971 |
Glibenclamide (HB 419, Daonil) in the clinical practice of diabetes.
Topics: Adult; Aged; Biguanides; Blood Glucose; Diabetes Mellitus; Female; Glyburide; Humans; Male; Middle A | 1971 |
Clinical experiences in oral antidiabetic therapy with sulphonylureas and biguanides.
Topics: Aged; Biguanides; Blood Glucose; Diabetes Mellitus; Glyburide; Humans; Insulin; Middle Aged; Phenfor | 1971 |
Glibenclamide--experience at Royal Prince Alfred Hospital 1967-70.
Topics: Adult; Aged; Blood Glucose; Diabetes Mellitus; Glyburide; Glycosuria; Humans; Hypoglycemic Agents; M | 1971 |
Clinical studies with glibenclamide at the Prince of Wales Hospital, New South Wales.
Topics: Aged; Biguanides; Diabetes Mellitus; Female; Glyburide; Humans; Male; Middle Aged; Sulfonylurea Comp | 1971 |
Symposium on diabetes mellitus and oral hypoglycaemic drugs. Summary.
Topics: Diabetes Mellitus; Glyburide; Humans; Hypoglycemic Agents; Insulin; Insulin Secretion; Structure-Act | 1971 |
[Behavior of serum insulin in the double intravenous glucose tolerance test in diabetics before and during glibenclamide therapy].
Topics: Aged; Diabetes Mellitus; Glucose Tolerance Test; Glyburide; Humans; Insulin; Middle Aged | 1971 |
[Clinical experience with glibenclamide, a new hypoglycemic agent].
Topics: Diabetes Mellitus; Glyburide; Humans | 1971 |
[Clinical evaluation of glibenclamide in the treatment of diabetes mellitus].
Topics: Administration, Oral; Adult; Diabetes Mellitus; Female; Glyburide; Humans; Male; Middle Aged | 1971 |
[Hypoglycemic coma caused by glibenclamide].
Topics: Adult; Coma; Diabetes Mellitus; Glyburide; Humans; Hypoglycemia; Male; Middle Aged | 1971 |
[4-year experience in using Daonil].
Topics: Diabetes Mellitus; Drug Evaluation; Glyburide; Humans | 1971 |